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Abstract 
 
Dendritic cells (DCs), the most potent antigen presenting cells, have been identified in 1973 by Ralph M. 
Steinman. DCs. DCs role as an immune initiator as well as regulator, have been intensively studied for 
their crucial function in regulating cellular and humoral immune responses. Efficiency of human vaccines 
is mostly dependent on the generation of proper humoral immunity, and recently T follicular helper (Tfh) 
cells have been identified as a true B cell helper, which significantly advanced our understanding of T 
cell-dependent B cell humoral immune responses. However, there are still little studies regarding the 
initial commitment of Tfh cells primed by DCs, particularly by the two major myeloid CD8α+ and CD8α− 
DC subsets. In this study, we present the undescribed intrinsic features and roles of the two DC subsets in 
the induction of Tfh cells and subsequent Tfh cell dependent humoral immune responses. We here 
demonstrate that the CD8α− DC subset critically roles in inducing antigen-specific Tfh cells by up-
regulated expressions of Icosl and Ox40l via the non-canonical NF-κB signaling pathway. CD8α− DCs are 
able to induce functional Tfh cells regardless of an adjuvant type. Tfh cells initially primed by CD8α− 
DCs function as a true B cell helper that results in dramatically enhanced humoral immune responses 
against various human pathogenic antigens such as Yersinia pestis LcrV, HIV Gag, and Hepatitis B 
surface antigen. In addition, we showed that the localization of CD8α− DCs in the marginal zone (MZ) 
bridging channels is closely related to the induction of CXCR5
+
CCR7
low
 Tfh cells. We also demonstrated 
that the major source of IL-6 for inducing Tfh cells is provided from the antigen specifically activated 
CD4
+
 T cells primed by CD8α− DCs, and those secreted by the DC subset seem have a minor role. 
Moreover, CD8α− DCs were superior in inducing functional Tfh cells over other antigen presenting cells 
majorly B cells. In contrast, CD8α+ DCs localized in the T cell enriched region are superior in inducing 
CXCR5
low
CCR7
high
 CD4
+
 T cells responsible for the generation of IFN-γ secreting Th1 cells. Taken 
together, this study reveals the undescribed intrinsic features and mechanistic role of the CD8α− DC 
subset in priming antigen-specific Tfh cell differentiation and thereby provides the potential of 
investigating CD8α− DCs to effectively evoke antigen-specific humoral immune responses through the 
improved therapeutic vaccines. 
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Chapter 1. Introduction 
 
1.1. Dendritic Cells 
 
1.1.1. History of dendritic cells 
The morphology of dendritic cells was initially observed by Paul Langerhans, thus it was initially named 
as Langerhans cells in the late 19
th
 century. The term dendritic cells was firstly introduced in 1973 by 
Ralph M. Steinman, who discovered the fundamental and crucial role of DCs in regulating innate and 
adoptive immune responses and DCs became placed at the center for the control of the complex immune 
system (Steinman and Cohn, 1973, Banchereau and Steinman, 1998). With his great contributions to the 
field of dendritic cell specially in its role in inducing adaptive immune responses, he received Albert 
Lasker Award for Basic Medical Research in 2007 and the Nobel Prize in Physiology or Medicine in 2011.  
 
1.1.2. Dendritic cells role as an immune initiator 
Dendritic cells (DCs) have been known as the most potent antigen presenting cells (APCs). Immature 
DCs uptake foreign antigens in the periphery, process the antigens and then present them in the form of 
peptide loaded major histocompatibility complex (MHC) on their surface. The antigen-bearing DCs then 
migrate to secondary lymphoid organs to induce antigen-specific T cell activation, cytotoxic CD8
+
 or 
CD4
+
 helper T cells. These antigen specifically educated T cells then go to the infected areas for pathogen 
clearance. Therefore, DCs play an important role in the induction of antigen-specific immune responses 
and thus they are known as an immune initiator (Banchereau and Steinman, 1998) (Figure 1-1). DCs do 
not selectively uptake foreign antigens, which means they uptake self or harmless antigens as well. But 
they only induce immune stimulatory responses against foreign antigens, and for harmless or self-antigens, 
they provide immune suppression responses. This phenomenon can be explained by DC maturation 
process. Foreign antigens but not self or harmless antigens provide DC maturation signal so that 
immature DCs become matured DCs, ready to educate antigen specific adaptive immune responses. They 
highly express MHC I and II, co-stimulatory molecules, and produce various cytokines leading to 
immune stimulation (Banchereau and Steinman, 1998) (Figure 1-2). In addition, DCs express toll-like 
receptors (TLRs) to recognize a variety of microorganism-derived molecular structures to efficiently 
initiate antigen specific immune responses as an immune initiator (Kaisho and Akira, 2003). 
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1.1.3. Dendritic cell migration 
DCs are nearly located throughout the body to efficiently induce immune responses against harmful 
pathogens. Immature DCs function as a sentinel randomly walking around in the body to encounter 
various antigens. The mobility and directionality of immature DCs is reported to be regulated by the 
concentration of myosin enriched at the rear or front of the DCs (Solanes et al., 2015, Chabaud et al., 
2015). Once immature encounter pathogenic antigens, they become matured and foreign antigen loaded 
mature DCs highly express CCR7 to migrate toward its corresponding chemokine, CCL19 or CCL21, 
secreted from secondary lymphoid organs where antigen specific T cells are educated by the mature DCs 
(Figure 1-3) (Banchereau and Steinman, 1998, Cyster, 1999, Steinman and Banchereau, 2007, Palucka 
and Banchereau, 2012). Regarding CCR7 dependent signaling pathways of DC migration, two 
independent pathways have been reported. Upon CCL19/21 stimulation, DC enhances its directionality 
via the JNK-c-Jun pathway, and/or its velocity via Rho-associated protein kinases (Iijima et al., 2005, 
Riol-Blanco et al., 2005). 
 
1.1.4. Dendritic cells as an immune regulator 
DCs are important not only to initiate but also to regulate immune responses. During antigen presentation 
by DCs, naive CD4
+
 T cells are antigen specifically educated and differentiated into several functional T 
cell subsets, and each T cell subset induces distinct immune responses (Deenick et al., 2011). For example, 
IL-12 produced by DCs differentiates naïve CD4
+
 T cells into IFN- γ producing Th1 cells and they are 
important for anti-viral infection, and TGF-β is responsible for inducing the regulatory T cells (Treg), 
important for immune regulation (Figure 1-4). Currently, secretory cytokines are known to often 
determine the fate of various effector CD4
+
 T cell subsets (Ottenhoff, 2012), however, besides these key 
cytokines, other factors such as antigen affinity, duration period and co-stimulatory molecules are also 
considered to be significantly involved in the differentiation of CD4
+
 helper T cell subsets. 
 
1.1.5. Myeloid dendritic cell subsets 
Among the various DC subsets characterized (Shortman and Liu, 2002), two major myeloid/conventional 
DC subsets in the secondary lymphoid organs are well-defined based on the expression of CD8α and their 
anatomic locations. CD8α+ DCs express the endocytic receptor, DEC-205, on their surface and are located 
in the T cell enrich zone within the lymphoid organs. They are known to be specialized in up-taking dying 
cells (Iyoda et al., 2002) and cross-presentation of non-replicating antigens, leading to cytotoxic CD8
+
 T 
cell priming (den Haan et al., 2000). In contrast, CD8α− DCs, known to specialize in MHC class II 
presentation (Dudziak et al., 2007), express a distinct uptake receptor, DCIR2, on their surface and they 
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are enriched in the bridging regions of the marginal zone or interfollicular zone (Figure 1-5 and Figure 1-
6) (Iyoda et al., 2002, Dudziak et al., 2007). These two DC subsets can be isolated and they are 
CD3
−
B220
−
CD11c
+CD8α+ and CD3−B220−CD11c+CD8α− DCs 
 
1.1.6. Dendritic cell subset targeting 
Delivering antigens to the distinct DC subset was successfully achieved by utilizing DC targeting strategy. 
DC targeting strategy by harnessing monoclonal antibodies (mAbs) (Swiggard et al., 1995, Nussenzweig 
et al., 1982) against endocytic receptors such as DEC-205 and DCIR2 expressed on the two DC subsets 
enriched our understanding of the functions of these DC subsets in inducing immune responses in vivo. 
Moreover, such targeting antibodies genetically conjugated with various pathogenic antigens have been 
validated in various disease models to improve vaccine efficacy and to develop novel therapeutics 
(Trumpfheller et al., 2012, Do et al., 2010). 
 
 
1.2. T follicular helper cells 
 
1.2.1. Function of T follicular helper cells 
T follicular helper (Tfh) cell was firstly observed in human tonsil in 2000 (Breitfeld et al., 2000, Schaerli 
et al., 2000). Tfh cells, identified as a true B cell helper, express CXCR5 highly, which help them to 
migrate into the germinal center where they help B cells to differentiate into plasma cells or memory B 
cells via cytokine or co-stimulation interaction (Figure 1-7) (Ma et al., 2012). Then, these B cells would 
serve for clearance of foreign pathogens and the establishment of long-term humoral immunity. Previous 
reports demonstrated Tfh cells are closely associated with humoral immunity related diseases such as 
autoimmunity, humoral immunodeficiency, and T cell lymphomas (Tangye et al., 2013). For example, one 
previous study showed the enhanced number of human immunodeficiency virus (HIV) -specific Tfh cells 
in chronic HIV-infected individuals, indicating the significance of Tfh cells responsible for the increased 
IgG titers seen in these patients (Lindqvist et al., 2012). It has been reported that the Tfh cell development 
initiates in the inter-follicular region/marginal zone (MZ) bridging channels (Kerfoot et al., 2011), 
however how Tfh cell differentiation is initially driven is not clearly understood. 
 
1.2.2. Characteristics of T follicular helper cells 
Distinct features of Tfh cells have been reported with high expressions of surface markers such as 
CXCR5, ICOS, PD1, SAP, OX40, low expression of CCR7, key cytokines such as IL-4, IL-6, IL-10, IL-
11 
 
21, and major transcription factors Bcl-6 and c-Maf, to be distinguished from other effector CD4
+
 T cells 
(Figure 1-7 and Figure 1-8) (Reinhardt et al., 2009, King, 2009, Crotty, 2011, Ma et al., 2012). Mutations 
in CD40L, ICOS, or SH2D1A (SAP) proteins in humans exhibited the reduced frequency of circulating 
CD4
+
CXCR5
+
 T cells in peripheral blood (Bossaller et al., 2006), and impaired Tfh-like function in X-
linked lymphoproliferative patients have been reported to be associated the reduced level of IL-10 
secretion from CD4
+
 T cells (Bossaller et al., 2006, Ma et al., 2005). 
 
1.2.3. Induction of T follicular helper cells 
The role of cognate B cells in the induction of Tfh cells was initially validated by several studies. 
Deficiency of both B cells and various B cell functional molecules, such as CD19, CD40, MHC class II 
and ICOSL, resulted in the decreased number of Tfh cells (Haynes et al., 2007, Johnston et al., 2009, 
Akiba et al., 2005, Deenick et al., 2010). In contrast, it has been demonstrated that continuous antigen 
presentation was sufficient to induce Tfh cell differentiation in B cell-deficient mice (Deenick et al., 2010) 
suggesting that other antigen-presenting cells (APCs) are essentially involved in Tfh cell differentiation. 
Moreover, a number of independent studies demonstrated that the induction of Tfh cells arise soon after 
priming by DCs (Vinuesa and Cyster, 2011, Baumjohann et al., 2011, Goenka et al., 2011, Choi et al., 
2011), and thus it appears that cognate B cells are generally required for maintaining Tfh cells, while DCs 
are necessary to prime naïve CD4
+
 T cells to differentiate into Tfh cells, especially at the early stage of 
Bcl6 up-regulation. However, detail mechanisms in the initial differentiation of Tfh cells by DCs were 
largely unknown. Particularly, the role of the two myeloid/conventional DC subsets in the induction of 
Tfh cells has not been studied. 
 
 
 
 
 
 
 
 
12 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1-1. The migratory role of dendritic cells in inducing adaptive immune responses (Banchereau and 
Steinman, 1998) 
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Figure 1-2. The features of immature and mature DCs (Banchereau and Steinman, 1998) 
 
 
 
 
 
 
Nature. Rev (1998). 392, 245-252. 
14 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1-3. Antigen specific T cells are induced by migratory mature DCs (Palucka and Banchereau, 
2012) 
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Figure 1-4. Dendritic cells induce distinct CD4
+
 T cell subsets (Deenick et al., 2011) 
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Figure 1-5. Anatomy of the spleen 
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Figure 1-6. The locations of myeloid DC subsets in the spleen (Dudziak et al., 2007) 
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Figure 1-7. Induction of Tfh cells and their function (Ma et al., 2012) 
JeM. (2012). 7, 1241-1253 
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Figure 1-8. The function of Tfh cells as a true B cell helper (King, 2009) 
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Chapter 2. CD8α− dendritic cell induces antigen-specific T follicular helper 
cells generating efficient humoral immune responses 
 
2.1. Introduction 
 
T follicular helper (Tfh) cells, newly identified CD4
+
 T cell subset, have been recognized as a true B cell 
helper (Ma et al., 2012, Crotty, 2011). Tfh cells highly express a B cell homing chemokine receptor, 
CXCR5, which leads their migration to germinal centers (GCs) in a CXCL13-dependent manner where 
they help cognate B cells to become antibody secreting cells (ASCs), plasma B cells, or memory B cells 
leading to efficient humoral immunity with long-term memory (Tangye and Tarlinton, 2009, Goodnow et 
al., 2010). Since the term Tfh cells was firstly introduced (Breitfeld et al., 2000, Schaerli et al., 2000), 
various studies have provided valuable data to characterize distinct features of Tfh cells such as high 
expressions of CXCR5, ICOS, PD1, and SAP, key cytokines such as IL-21 and recently IL-4 (Reinhardt 
et al., 2009) and major transcription factors Bcl6 and c-Maf, to be distinguished from other CD4
+
 T helper 
cells (Ma et al., 2012, Crotty, 2011). Given the fact that efficient Tfh cell-dependent humoral immunity as 
well as long-term humoral memory responses are an essential defensive arm of the vertebrate immune 
system, it is not surprising that aberrant Tfh cell development or its dysfunctional activity has been known 
to be closely associated with various human diseases such as autoimmunity, humoral immunodeficiency, 
and T cell lymphomas (Tangye et al., 2013). Thus, an understanding of the initiation and the regulation of 
Tfh cells is critical to improve vaccine efficacy as well as to design effective novel therapies. 
The role of cognate B cells in the induction of Tfh cells has been validated by several studies. 
Deficiency of not only B cells but also various B cell functional molecules, such as CD19, CD40, MHC 
class II and ICOSL, results in the significant decreased number of Tfh cells (Haynes et al., 2007, Johnston 
et al., 2009, Akiba et al., 2005, Deenick et al., 2010). In addition, interaction between CD4
+
 T cells and 
cognate B cells via SAP, a cytoplasmic adaptor protein of the SLAM family, was shown to be critical in 
inducing Tfh cells (Cannons et al., 2010). In contrast, another study has demonstrated that continuous 
antigen presentation was sufficient enough to induce Tfh cell differentiation without cognate B cells 
(Deenick et al., 2010), suggesting that other antigen-presenting cells (APCs) have a major role in Tfh cell 
differentiation. Moreover, a number of recent studies showed that Tfh cells could arise soon after priming 
by dendritic cells (DCs) (Vinuesa and Cyster, 2011, Baumjohann et al., 2011, Goenka et al., 2011, Choi et 
al., 2011), and thus that cognate B cells may be generally required for maintaining functional Tfh cells, 
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while DCs have a major role in priming Tfh cells, especially at the early stage of Bcl6 up-regulation in 
Tfh cells. 
Although some molecules of DCs have been reported to be critically involved in the induction of 
Tfh cells (Choi et al., 2011, Fillatreau and Gray, 2003, Cucak et al., 2009), how DCs mechanistically 
prime naïve CD4
+
 T cells to become Tfh cells, differently from various CD4
+
 effector T cell subsets still 
remain unclear. Particularly, the roles of two distinct CD8α+ and CD8α− DC subsets in the secondary 
lymphoid organs in inducing Tfh cells are largely unexplored. Among various DC subsets characterized 
so far (Shortman and Liu, 2002), two major myeloid DC subsets in the secondary lymphoid organs are 
well-defined based on the expression of CD8α and their anatomic locations. CD8α+ DCs express the 
endocytic receptor, DEC-205, and they are located in the T cell enriched zone of the lymphoid organs. 
They are specialized in up-taking dying cells (Iyoda et al., 2002) and in cross-presentation of non-
replicating antigens, leading to cytotoxic CD8
+
 T cell induction (den Haan et al., 2000). In contrast, 
CD8α− DCs, specialized in MHC class II presentation (Dudziak et al., 2007), express a distinct uptake 
receptor, DCIR2, and they are located in the bridging regions of the marginal zone (Iyoda et al., 2002). A 
DC targeting strategy by harnessing monoclonal antibodies (mAbs) (Swiggard et al., 1995, Nussenzweig 
et al., 1982) against various endocytic receptors, e.g. DEC-205 and DCIR2, expressed on the surface of 
DC subsets enhanced our understanding of the roles of these DC subsets in vivo. Moreover, conjugating 
such DC subset receptor specific targeting antibodies with a wide range of pathogenic antigens has been 
validated in various disease models to improve vaccine efficacy and to effective deliver novel therapeutic 
approaches (Trumpfheller et al., 2012, Do et al., 2010). 
In this study, we utilized both DC subset-targeting mAbs and DC subset-sorting strategies to 
study how these two distinct myeloid DC subsets differently prime Tfh cell differentiation by unveiling 
their underlying mechanisms and signaling pathways. Our data demonstrate that functional Tfh cells are 
efficiently primed by the CD8α− DC subset in vivo via the enhanced expressions of ICOSL and OX40L on 
CD8α− DCs through the non-canonical NF-κB pathway, leading to efficient humoral immune responses 
against various human pathogenic antigens (Shin et al., 2015). 
 
 
 
 
 
 
 
26 
 
2.2. Experimental Procedures 
 
Mice 
Naïve BALB/c (BC, H-2
d
) and C57BL/6 (B6, H-2
b
) mice were purchased from Taconic. DO11.10 Thy 
1.1, OT-II, RAG-1-deficient, CXCR5 KO, IL-4R KO and IL-12p40 KO mice were purchased from The 
Jackson Laboratory. IL-21R KO mice were kindly provided from The Rockefeller University (the late Dr. 
Ralph M. Steinman, New York, NY, USA). SLAM-associated protein or SAP KO mice were generously 
provided by Dr. Pamela L. Schwartzberg from National Human Genome Research Institute, National 
Institutes of Health (Bethesda, MD, USA). All mice were properly maintained under specific pathogen-
free conditions and used at 6-8 weeks, approved by Ulsan National Institute of Science and Technology 
Institutional Animal Care and Use Committee (approval number: UNISTIACUC-12-006-A). 
 
Dendritic cell preparation 
Total number of splenic dendritic cells was increased by using Fms-like tyrosine 3 ligand (Flt3L) as 
described (Dudziak et al., 2007). Briefly, 5 × 10
6 
cells of B16Flt3L-melanoma cells were subcutaneously 
(s.c.) injected to naïve C57BL/6 mice. After 10-14 days, the expanded splenic CD11c
+
 DCs were isolated 
with positive magnetic-activated cell sorting (MACS; Miltenyi Biotec, GmbH, Bergisch Gladbach, 
Germany) and were further sorted into two DC subsets, CD3
−
B220
−
CD11c
+
CD8α+ or 
CD3
−
B220
−
CD11c
+
CD8α− DCs by MoFlo XDP (Beckman Coulter, Brea, CA, USA). To analyze intrinsic 
differences in the two DC subsets, the DCs were stimulated either with 25 µg of poly (I:C) or 100 ng/ml 
of LPS for 0, 12 or 24 hours. In some experiments, 10 µM of a NIK inhibitor (4H-isoquinoline-1,3-dione, 
combi-Blocks, San Diego, CA, USA) (Ranuncolo et al., 2012) was treated to the two DC subsets. 
 
CD4
+
 T cell preparation 
OVA-specific transgenic CD4
+
 T cells from the lymph nodes and the spleen of OT-II or DO11.10 Thy1.1 
mice were negatively purified by using hybridoma supernatant cocktails of rat-anti mouse -CD8 (2.43), -
MHC class II (T1B120), -Mφ (F4/80), -B220 (RA3-6B2), and -NK cell (NK1.1) antibodies and then 
depleted with dynabeads sheep anti-rat IgG (Invitrogen, Carlsbad, CA, USA). 
 
Induction of Tfh cells in vitro 
Naive OVA-specific CD4
+
 T cells isolated from OT-II mice were co-cultured with purified CD8α+ or 
CD8α− DCs (1:10 ratio of DC to T cells) for 1 ~ 6 days in the presence of 25 µg/ml of poly (I:C), 100 
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ng/ml of LPS, Flagellin or R848 (Invivogen, San Diego, CA, USA) ± 2 µM of OVA peptide (a.a. 323-339) 
(Genscript, Piscataway Township, NJ, USA). At each indicated time point, activated Vα2+CD4+CD44+ T 
cells were isolated, and analyzed for the expression of various surface molecules, transcription factors, 
and cytokines by flow cytometry, qRT-PCR, and ELISA methods. To block ICOSL or OX40L expressed 
on the DC subsets, 20 µg/ml of blocking antibodies or their corresponding isotype antibodies were treated 
when CD4
+
 T cells were co-cultured with the DC subsets for 3 days.  
 
Induction of Tfh cells in vivo 
Harvested CD4
+
 T cells from DO11.10 Thy 1.1 mice were adoptively transferred (3 × 10
6 
cells per mouse) 
into naïve Thy 1.2
+
 BALB/c mice intravenously (i.v.) at day -1. At day 0, PBS, 500 µg of soluble OVA 
protein (endotoxin-free; Seikagaku Corp, Tokyo, Janpan), or 5 µg of each distinct DC subset targeting 
monoclonal antibodies (anti-DEC-205 or anti-DCIR2 mAbs) conjugated with OVA protein in the 
presence of 50 µg of poly (I:C) or LPS were s.c.  injected via footpads. At indicated time points, single 
cells from the lymph nodes or the spleen were harvested and analyzed for the expressions of various 
molecules by flow cytometry. In some experiments, 100 µg of Isotype, ICOSL, or OX40L blocking mAbs 
were i.v. injected to the immunized mice at day 0 and 2. Then, 4 days after the immunization, cells were 
harvested for analysis. 
 
Intracellular staining 
Antigen specific Tfh cells were induced in vivo as described above. Five days later, single cells were 
harvested from the lymph nodes or the spleen, and Fcγ receptors were properly blocked with anti-
CD16/CD32 antibodies. The cells were then stained with anti-mouse Thy1.1 or DO11.10, CD4, CD44 
and CXCR5 for 30 minutes at R.T. Following fixation and permeabilization with a Cytofix/Cytoperm kit 
(BD Biosciences, San Jose, CA, USA) according to the manufacturer’s instructions, the cells were then 
stained for intracellular Bcl6 or IL-21 along with their corresponding isotypes for 25 minutes at 4 °C. 
Data were obtained by flow cytometry. To detect IFN-γ or IL-4 secreting CD4+ T cells, the cells were re-
stimulated with 2µM of OVA peptide (323-339) in the presence of 2 µg/ml αCD28 mAbs for 2 hours 
followed by the treatment of GolgiStop (Invitrogen) for 4 hours.  
 
Production of DC subset-specific targeting antibodies conjugated with various antigens 
In this study, we utilized three different proteins conjugated with DC subset-specific targeting antibodies 
(Do et al., 2010, Trumpfheller et al., 2012). LcrV, HIV gagp24, and OVA proteins were genetically 
conjugated either to anti-mouse DEC-205 (for CD8α+ DC targeting) mAbs or to anti-mouse DCIR2 (for 
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CD8α− DC targeting) mAbs. No significant antigen-specific immune responses were detected with each 
matched isotype control (data not shown). LcrV and HIV gagp41 proteins were used as described in the 
previous studies (Do et al., 2010, Trumpfheller et al., 2012). All proteins utilized were free of endotoxin 
(<0.125 endotoxin units/mg) in a Limulus Amebocyte Lysate assay, QCL-1000 (Bio Whittaker). 
 
In vivo immunization with DC subset targeting antibodies 
Mice were intraperitoneally (i.p.) or subcutaneously (s.c.) injected with LcrV- or HIV gagp24-protien 
conjugated mAbs (5 or 10 µg per mouse) in the hind footpads in the presence of adjuvant (50 µg poly (I:C) 
+/- 25 µg anti-CD40 antibody per mouse). For some experiments, a priming and boosting strategy was 
applied where mice were primed and then boosted 4-6 weeks apart with LcrV- or HIV gagp24-protein 
conjugated targeting mAbs (5 or 10 µg per mouse) in the presence of 50 µg poly (I:C). 
 
Adoptive transfer experiment to RAG-1-deficient mice in the presence of OVA or HBsAg 
Naïve OVA-specific CD4
+
 T cells were activated by each DC subset for 3 days, isolated (CD4
+
CD44
+
 T 
cells), and then adoptively transferred (2 × 10
6 
cells per mouse) i.v. into RAG-1-deficient mice together 
with naïve CD19
+
 B cells (4 × 10
6 
cells per mouse) at day -1 followed by i.p. injection of 500 µg soluble 
OVA protein in the presence of 50 µg poly (I:C) at day 0. 10 days after the immunization, the RAG-1-
deficient mice were boosted i.p. with 500 µg soluble OVA protein and 50 µg poly (I:C). Seven days after 
the boost, total splenocytes were obtained and ELISPOT assay of anti-OVA ASCs was performed. For 
HBsAg, naive CD4
+
 T cells were activated by each DC subset for 3 days with 10 µg/ml  HBsAg (LG life 
sciences, Seoul, south Korea) and 25 µg/ml poly (I:C), isolated, and then adoptively transferred (1 × 10
6 
cells per mouse) i.v. into RAG-1-deficient mice together with sorted naïve CD19
+
 B cells (4 × 10
6 
cells 
per mouse) at day -1 followed by i.p. injection of 50 µg HBsAg with 50 µg poly (I:C) at day 0. 10 days 
after the immunization, the RAG-1-deficient mice were boosted i.p. with 50 µg soluble HBsAg and 50 µg 
poly (I:C). Seven days after the boost, total splenocytes were obtained and ELISPOT assay of anti-HBs 
ASCs was performed. 
 
ELISPOT assay for antibody-secreting cells 
In order to detect antigen-specific ASCs, ELISPOT plates (Millipore, Billerica, MA, USA) were coated 
with 5 or 10 µg/ml LcrV, Gagp41, OVA, or HBsAg protein overnight at 4 °C. After the plates were 
washed, blocked with RPMI 5% FBS (Gibco, Grand Island, NY, USA) for 1 hour at 37 °C. Serially 
diluted cells from the spleen, lymph nodes, or bone marrow were incubated for 6 hours at 37 °C. The 
plates were washed and then stained with goat anti-mouse Fc specific IgM, IgG or IgG1 antibody 
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conjugated with horseradish peroxidase (Southern Biotech, Birmingham, AL, USA) for 2 hours at room 
temperature. The plates were developed by a peroxidase substrate AEC kit (Vector Laboratories, 
Burlingame, CA, USA). Visible spots were counted by an ELISPOT reader (Autoimmune Diagnostika 
GmbH, Straßberg, Germany). 
 
ELISA for serum antibodies and cytokines 
High binding ELISA plates (BD Bioscience) were coated with 5 or 10 µg/ml LcrV, Gagp41, OVA, NP8-
BSA, or NP30-BSA protein overnight at 4 °C. The plates were washed 3 times with PBST (PBS with 0.1% 
of Tween 20) and then blocked with PBST-BSA 5% for 1 hour at 37 °C. Serial dilutions of mouse serum 
were added into the plates and then incubated for 1 hour at 37 °C. Various secondary goat anti-mouse Fc 
specific antibodies conjugated with horseradish peroxidase were utilized and developed with o-
phenylenediamine (Sigma-Aldrich, St. Louis, MO, USA) tablets at room temperature for 15~20 minutes. 
Data are presented as log antibody titers with the highest dilution showing OD450 >0.1. To detect 
cytokines in supernatants of the cell culture, we used CBA flex sets (BD Bioscience). 
 
ChIPs 
The two DC subsets were treated with or without 25 µg/ml poly (I:C) for 2 hours followed by a ChIP 
assay using a magna ChIP kit (Millipore). Briefly, the two DC subsets were treated with 37% 
formaldehyde, 1% in the final solution, for protein-chromatin DNA cross-linking, and then glycine was 
treated to remove excess formaldehyde. The cells were then sonicated to contain ~500 bp DNA fragments 
with the Sonic Dismembrator 500 (Fisher Scientific, Waltham, MA, USA). The DNA fragments were 
precipitated with mouse IgG2a isotype control, anti-moue p52, or anti-acetyl-histone H3 antibodies. The 
precipitants were treated with 100 µg/ml proteinase K to remove proteins and then incubated for 2 hours 
at 62 °C to reverse cross-linking. Finally, purified DNA was amplified by qPCR (LightCycler 480 SYBR 
Green I Master, Roche, Clovis, CA, USA). Data were expressed as enrichment related to input. 
 
Immunohistochemistry 
Briefly, tissue sections (10 µm) of the spleen were obtained by using Cryotome (Thermo Fisher scientific, 
thermos, Carlsbad, CA, USA) and then they were fixed with 100% aceton on a slide. To obtain germinal 
center images, slides were stained with APC anti-mouse IgD (BD Biosciences) and FITC anti-mouse 
PNA (Vector Laboratories). Then, the stained samples were imaged with FV10i confocal microscope 
(Olympus, Center Valley, PA, USA). 
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Flow cytometry 
Information on all antibodies used for flow cytometry analysis is listed below. Data were acquired by BD 
FACS Calibur or BD LSRfortessa, and the data were analyzed by FlowJo software (Tree Star Inc., 
Ashland, OR, USA), shown on the log scale graph (from 10
1
 to 10
4
 or 10
5
). All data values were obtained 
after subtracting their corresponding isotype values.  MFI stands for Median Fluorescence Intensity. 
 
Antibodies for flow cytometry and FACS 
Antigen Clone Fluorochrome Company 
DC subset isolation    
CD11c HL3 PE BD Biosciences 
CD8 53-6.7 APC BD Biosciences 
CD3 145-2C11 FITC BD Biosciences 
B220 RA3-6B2 FITC BD Biosciences 
CD4
+ 
T cell analysis    
Vα2 B20.1 FITC BD Biosciences 
Thy1.1 OX-7 FITC BD Biosciences 
DO11.10 KJ1-26 FITC/PE BD Biosciences 
CD4 RM4-5 APC BD Biosciences 
CD44 IM7 Pe-Cy7/APC-Cy7 BD Biosciences 
CXCR5 2G8 PE/Biotin BD Biosciences 
ICOS 7E.17G9 PE/Biotin BD Biosciences 
PD1 RMP1-30 Biotin/APC eBioscience 
Intracellular staining    
Bcl6 K112-91 PE BD Biosciences 
IL-4 11B11 PE BD Biosciences 
IFN-γ XMG1.2 PE BD Biosciences 
IL-21 mhalx21 PE eBioscience 
DC subsets analysis    
ICOSL HK5.3 Biotin eBioscience 
OX40L RM134L Biotin eBioscience 
PDL1 MIH5 Biotin eBioscience 
PDL2 TY25 Biotin eBioscience 
31 
 
Antibodies for flow cytometry and FACS 
GC B cell analysis    
CD19 1D3 PE BD Biosciences 
IgD 11-26C.2A APC BD Biosciences 
FAS Jo2 Pe-cy7 BD Biosciences 
GL7 GL7 FITC BD Biosciences 
Streptavidin Streptavidin PE/PE-cy7/APC/BV421 BD Biosciences 
Isotype control    
Rat IgG2a, κ 
R35-95/ 
RTK2758/2A3 
PE/Biotin/ Purified 
BD/ 
BioLegend/Bioxcell 
Rat IgG2b, κ 
A95-1/ 
RTK4530/LTF-2 
PE/APC/Biotin/purified 
BD/ 
BioLegend/Bioxcell 
Mouse IgG1, κ MOPC-21 PE BD Biosciences 
Functional antibody    
CD40 1C10 purified BD Biosciences 
ICOSL HK5.3 Functional grade purified 
eBioscience, 
Bioxcell 
OX40L RM134L Functional grade purified 
eBioscience, 
Bioxcell 
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Western blot analysis 
The two DC subsets were stimulated with or without 25 µg/ml poly (I:C) or 0.5 µg/ml  anti-CD40 
antibody for 2 hours at 37 °C followed by western blot (WB) analysis. WB images were developed with 
LAS 4000 (GE Healthcare, Cleveland, Ohio, USA). Information on all WB antibodies is listed below. 
 
Antibodies for western blot and chip assay 
Antigen Clone Application Company 
Western Blot    
Total NIK polyclonal WB Cell Signaling 
Phospho-p100 polyclonal WB Cell Signaling 
Total-p100/p52 polyclonal WB Cell Signaling 
Total-RelB C-19 WB Santa Cruz 
Phospho-ERK polyclonal WB Cell Signaling 
Total-ERK 137F5 WB Cell Signaling 
Phospho-JNK polyclonal WB Cell Signaling 
Total-JNK 37/pan-JNK/SAPK1 WB BD Biosciences 
Phopho-p38 D3F9 WB Cell Signaling 
Total-p38 27/p38α/SAPK2a WB BD Biosciences 
Beta−actin AC-15 WB Ambion 
Chip assay    
Mouse IgG2a, κ G155-178 Chip BD Biosciences 
NFκB p52 c-5 Chip Santa Cruz 
Acetyl Histone H3 polyclonal Chip Millipore 
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qRT-PCR analysis 
Total RNA was obtained with Trizol (Invitrogen), and cDNA was synthesized by using a cDNA synthesis 
kit (NEB, Ipswich, MA, USA). Light Cycler 480 II was utilized to perform a SYBR Green based qPCR 
experiment. House-keeping genes, β-actin and Gapdh, were applied for normalization. Information on all 
primers is listed in below. 
 
Primers for qRT-PCR and chip assay 
Genes Forward Reverse 
qRT-PCR   
ICOS 5'-TGACTGGCTTTGTTAGGG-3' 5'-TGTTAGGTGTTCGTGTTGG-3' 
SAP 5'-GTACCACGGCAAAATCAG-3' 5'-GTACACGCCAGGGACAC-3' 
Bcl6 5'-CTTCCCACACTGCCATAΑ−3' 5'-GCATTCTCCCCTACTTTGΑ−3' 
c-maf 5'-CCCTCCTTCTGAGTTCTTCT-3' 5'-GAGTGGCTTTAGTTCATTCTGT-3' 
T-bet 5'-TGGAGGTGAATGATGGAG-3' 5'-ATCTCTGCGTTCTGGTAGG-3' 
Beta−Actin 5'-TCCTATGTGGGTGACGAG-3' 5'-CTCATTGTAGAAGGTGTGGTG-3' 
GAPDH 5'-AAGGACACTGAGCAAGAGAG-3' 
5'-GATGGTATTCAAGAGAGTAGGG-
3' 
Chip 
Assay 
  
ICOSL 5'-TGGTGGTGCATAGTTTCCAΑ−3' 5'-TTCCCCACAACATCTGGAAT-3' 
OX40L 5'-CTCTCCCAATGGTCTCCAAΑ−3' 5'-TTATCATGGAGCCGTCAACΑ−3' 
GAPDH 5'-ACCAGGGAGGGCTGCAGTCC-3' 5'-TCAGTTCGGAGCCCACACGC-3' 
CCL2 5'-CTGGAGCTCACATTCCAGC-3' 5'-GGATGTTCTTCCCAGCG-3' 
 
 
Statistics 
Results are expressed as mean ± s.e.m. or mean ± s.d. We used a PRISM 4.0 or EXCEL program 
(GraphPad Prism, La Jolla, CA, USA) and performed nonparametric Mann-Whitney U test when 
appropriate. P values < 0.05 were considered significant. 
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2.3. Results 
 
CD8α− DCs augment the generation of Tfh cell-dependent antibody secreting cells 
In order to inspect if the two DC subsets have different functions in the generation of Tfh cell-dependent 
antigen-specific antibody secreting cells (ASCs) in vivo, we used distinct DC subset targeting monoclonal 
antibodies (mAbs) conjugated with LcrV (V) protein from Yersinia pestis, anti-DEC-205:V (for targeting 
CD8α+ DCs) and anti-DCIR2:V (for targeting CD8α− DCs) conjugated mAbs. We observed significant 
numbers of anti-V ASCs both in the spleen and the bone marrow harvested from CD8α– DC targeted 
groups, while little ASCs were observed from the CD8α+ DC targeted groups (Figure 2-1A). The total 
number of ASCs in the spleen was significantly decreased after 28 days of the immunization, while ASCs 
in the bone marrow were increased confirming the previously reported fact that long-lived ASCs live in 
the bone marrow (Slifka et al., 1995). Similar phenomenon was observed by using a different mouse 
strain (Figure 2-1B), demonstrating that the increased number of ASCs by targeting CD8α− DCs is not 
limited to a particular MHC haplotype. 
We then examined the number of anti-V ASCs in various Tfh cell related KO mice. We observed 
that anti-V ASCs induced by targeting CD8α− DCs were dramatically decreased in CXCR5 (Breitfeld et 
al., 2000)-, SAP (Qi et al., 2008)-, IL-21 (Nurieva et al., 2008) receptor (R)-KO mice (Figure 2-1C), but 
such decreases were not detected in IL-12p40- (Mosmann and Coffman, 1989, Ma et al., 2009) or IL-4R 
(Kaplan et al., 1996)-KO mice (Figure 2-1D). Taken together, these data clearly demonstrated that CD8α− 
DCs enhance the generation of Tfh cell-dependent antigen-specific ASCs. 
 
CD8α− DCs specialize in inducing antigen-specific Tfh cells in vivo 
To investigate functions of the two DC subsets in the induction of antigen-specific Tfh cells in vivo, we 
employed DC subset targeting strategy through ovalbumin (OVA)-conjugated mAbs and OVA transgenic 
mice. Five days after the immunization, we observed higher percentages and numbers of CXCR5
+
PD1
+
, 
CXCR5
+
Bcl6
+
, and CXCR5
+
IL-21
+ 
Tfh cells both in the lymph nodes and the spleen from the CD8α− DC 
targeted group (Figures 2-2A-C; Figures 2-3B-D). 
In order to confirm the capability of CD8α− DCs in inducing Tfh cells in vivo under different 
stimulatory cues, similar experiments were performed with LPS. Again, higher percentages and numbers 
of CXCR5
+
PD1
+
, CXCR5
+
Bcl6
+
, and CXCR5
+
IL-21
+
 Tfh cells were induced by CD8α− DCs both in the 
lymph nodes and the spleen compared with those induced by CD8α+ DCs (Figures 2-2D-F; Figures 2-
4B-D). We observed no significant difference in the total number of DO11.10
+
CD4
+
 T cells induced by 
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the two DC subsets in the lymph nodes (Figure 2-2G). In the spleen, however, we observed higher total 
number of DO11.10
+
CD4
+
 T cells in the CD8α− DC targeted group (Figure 2-3E; Figure 2-4E). Once the 
numbers of Tfh cells were normalized by the total number of DO11.10
+
CD4
+
 T cells in each DC subset 
targeted group, we still observe greater number of Tfh cells induced in the CD8α− DC targeted group 
(Figure 2-3F; Figure 2-4F). As previously studied (Do et al., 2010), CD8α+ DCs were superior in 
inducing higher number of IFN-γ+CD4+ T cells regardless of total number of DO11.10+CD4+ T cells 
(Figure 2-4G), while CD8α− DCs are more potent in inducing IL-4 secreting CD4+ T cells (Figure 2-4H). 
Taken together, our data clearly demonstrate that targeting CD8α− DCs specialize in inducing antigen-
specific Tfh cells in vivo. 
 
CD8α─ DCs are superior in inducing Tfh cells in vitro 
To confirm that our observation on Tfh cells induced in vivo is due to intrinsic differences between the 
two DC subsets, CD8α+ DCs and CD8α− DCs, and not due to DC subset receptor-specific responses via 
DC targeting mAbs, the two DC subsets were purified and the induction of antigen-specific Tfh cells by 
each DC subset was compared in vitro. At the indicated time point after the co-culture of OVA-specific 
OT-II CD4
+
 T cells with either CD8α+ or CD8α− DCs, the activated CD44+CD4+ T cells were isolated and 
then analyzed for Tfh cell-related surface markers, transcription factors, and cytokines. Interestingly, we 
observed the higher ICOS expression on the CD4
+
 T cells induced by CD8α− DCs as early as day 2 
followed by the enhanced Bcl6 expression at day 3 (Figures 2-5A-C; Figure 2-6A), which clearly 
supports the previously suggested theory on a molecular hierarchy from ICOS to Bcl6 (Choi et al., 2011). 
The expressions of SAP and c-Maf (Bauquet et al., 2009) were also highly increased in the CD4
+
 T cells 
induced by CD8α− DCs, whereas T-bet, a transcription factor of Th1 cell, was highly identified in those 
induced by CD8α+ DCs (Figure 2-5C; Figure 2-6A). Again, such phenomena were not restricted to a 
particular DC maturation cue, poly (I:C). Data showed that the CD4
+
 T cells induced by CD8α− DCs with 
LPS expressed higher levels of CXCR5 and ICOS (Figure 2-5D), Bcl6 (Figure 2-5E), and greatly 
secreted IL-21 (Figure 2-5F). Moreover, with Toll-like Receptor 5 (TLR5) (flagellin) and TLR7/8 (R848) 
stimuli, the CD4
+
 T cells induced by CD8α− DCs secreted higher level of IL-21 cytokine compared with 
that secreted from the CD4
+
 T cells induced by CD8α+ DCs (Figure 2-5F). We observed no significant 
difference in total CD4
+ 
T cell proliferation induced by the two DC subsets in vitro (Figure 2-6B). 
In order to validate the role of in vitro induced Tfh cells as a true B cell helper, the in vitro 
generated DC subset-primed CD4
+
 T cells were adoptively transferred together with naïve CD19
+
 B cells 
into RAG-1-deficient mice. After prime and boost immunizations with soluble OVA protein, we observed 
higher number of anti-OVA ASCs in the group which received the Tfh cells induced by CD8α− DCs 
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(Figure 2-5G). Together, these data clearly show that CD8α− DCs are superior in inducing antigen-
specific Tfh cells in vitro. 
 
CD8α─ DCs efficiently increase germinal center (GC) formation, reaction, and antibody titers  
After we observed the capability of CD8α− DCs in inducing Tfh cells both in vitro and in vivo, we 
examined whether CD8α− DC induced Tfh cell functions as a true B cell helper. As expected, higher 
percentage of CD19
+
IgD
–
GL7
+
FAS
+
 GC B cells was observed in total splenocytes harvested from the 
CD8α− DC targeted group under different stimuli cues (Figures 2-7A and B; Figures 2-8A and B). 
Histologically, the formation of PNA
+
 cells well surrounded by IgD
+
 cells in the spleen from the CD8α− 
DC targeted group was detected, whereas we observed no GC formation in the CD8α+ DC targeted group 
(Figure 2-8C). In addition, the CD8α− DC targeted group demonstrated higher titers of both anti-OVA 
IgM and IgG antibodies than those from the CD8α+ DC targeted group (Figure 2-7C). Titer level of anti-
OVA IgM induced by CD8α− DCs was much higher than those induced by CD8α+ DCs at day 5, which 
were isotype-switched to IgG at day 5. In the CD8α+ DC targeted group, isotype-switched anti-OVA IgG 
was notably identified 7 days after the immunization, but its titer level was still lower than those from the 
CD8α− DC targeted group. To further ensure the increased GC reaction in the CD8α− DC targeted group, 
we inspected affinity maturation of antibodies using NP-OVA. Briefly, 10 days after the immunization, 
the mice were re-immunized with 10 µg NP16-OVA. 7 and 14 days after the re-immunization, higher ratio 
of NP8 to NP30 of anti-OVA IgG antibodies was induced by CD8α
− 
DCs compared with those induced by 
both soluble OVA protein and CD8α+ DCs (Figure 2-7D). These data strongly demonstrate that the 
CD8α− DC subset is an inducer of functional Tfh cells, generating efficient humoral immune responses in 
vivo. 
 
Up-regulated ICOSL and OX40L expressed on CD8α− DCs play a critical role in inducing Tfh cells 
In order to study distinct features between the two DC subsets in the induction of Tfh cells, various Tfh 
cell related ligands on the DC subsets were compared under poly (I:C) or LPS stimulus. Higher 
expression levels of ICOSL (Choi et al., 2011) and OX40L (Fillatreau and Gray, 2003) were observed in 
CD8α− DCs in the presence of both poly (I:C) (Figure 2-9A) and LPS (Figure 2-9B), whereas higher 
expression levels of PDL1 and PDL2 (Figures 2-10A and B), which are reported to negatively control 
Tfh-dependent humoral immune responses (Cubas et al., 2013, Hams et al., 2011), were observed in 
CD8α+ DCs. When ICOSL on the two DC subsets was blocked with anti-ICOSL blocking antibodies 
during DC-T cell co-culture, the formerly enhanced expressions of CXCR5 and ICOS on the CD4
+
 T cells 
primed by CD8α− DCs were decreased to the level as those induced by CD8α+ DCs (Figure 2-9C; Figure 
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2-10C). Interestingly, blocking OX40L on CD8α− DCs with anti-OX40L blocking antibodies during DC-T 
cell co-culture also reduced expression levels of both CXCR5 and ICOS as much as those induced by 
CD8α+ DCs (Figure 2-9C; Figure 2-10C). To further check the functions of enhanced expressions of 
ICOSL and OX40L on CD8α− DCs in inducing Tfh cells in vivo, blocking antibodies against ICOSL or 
OX40L were applied during distinct DC subset targeting. The increased expression of CXCR5 on the 
CD4
+
 T cells induced by CD8α− DCs was decreased by blocking either ICOSL or OX40L (Figure 2-9D). 
Moreover, blocking either ICOSL or OX40L on CD8α− DCs significantly reduced the number of 
CXCR5
+
PD1
+
, CXCR5
+
Bcl6
+
, or CXCR5
+
IL-21
+
 Tfh cells primed by CD8α− DCs both in the lymph node 
(Figure 2-9E) and the spleen (Figure 2-10D). Thus, the data clearly demonstrate the critical role of both 
ICOSL and OX40L signaling in CD8α− DCs for Tfh cell differentiation. 
 
Increased non-canonical NF-κB signaling pathway in CD8α− DCs regulates Icosl and Ox40l gene 
expressions 
Based on the previous study demonstrating that the non-canonical NF-κB signaling pathway regulates 
high level of ICOSL expression in B cells (Hu et al., 2011) and based on our analysis of the non-canonical 
NF-κB signaling pathway in the two DC subsets from the published gene array data (Dudziak et al., 2007), 
we hypothesized that the enhanced expressions of ICOSL and OX40L on CD8α− DCs are controlled by 
the non-canonical NF-κB signaling pathway. Interestingly, we observed higher level of NF-κB-inducing 
kinase (NIK), a signal integrator of the non-canonical NF-κB pathway (Sun, 2011), in CD8α− DCs even in 
the absence of stimulation and its expression was further enhanced upon poly (I:C) stimulation, whereas it 
was barely measurable in CD8α+ DCs (Figure 2-11A; Figure 2-12A). When anti-CD40 stimulation 
(Coope et al., 2002), which is reported to elicit strong signals through both the canonical and non-
canonical signaling pathways, was given to the two DC subsets, the expression level of NIK was 
enhanced in the two DC subsets, but its expression level was still higher in CD8α− DCs (Figure 2-11A; 
Figure 2-12A). In addition, we observed greater expression levels of phospho(p)-p100, p52, and RelB in 
CD8α− DCs in the absence or presence of stimulation (Figure 2-11A; Figure 2-12A). In contrast, CD8α+ 
DCs constitutively expressed higher levels of molecular components involved in the pro-inflammatory 
MAPK signaling pathway, particularly p-JNK, which was barely detectable in CD8α− DCs (Figure 2-11B; 
Figure 2-12A). To confirm if the promoter of Icosl or Ox40l links with the non-canonical NF-κB 
signaling pathway, ChIP experiments were performed. We quantified the enriched DNA obtained from the 
immunoprecipitates by qPCR using primers spanning the upstream regions of Icosl or Ox40l (Figure 2-
12B). Upon poly (I:C) stimulation, we observed that the significant enrichment of p52 was associated 
with the upstream region of Icosl (-3000) or Ox40l (-1000) in CD8α− DCs (Figure 2-12C). We used 
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Gapdh and Ccl2 genes as negative and positive controls for p52, respectively (Figure 2-12C). In addition, 
when a NIK inhibitor (4H-isoquinoline-1,3-dione) was applied, the formerly increased expressions of 
ICOSL and OX40L on CD8α− DCs were significantly decreased (Figure 2-11D). Therefore, our findings 
obviously showed that intrinsically increased non-canonical NF-κB signaling pathway regulates the 
enhancement of ICOSL and OX40L expressions on CD8α− DCs. 
 
Employing CD8α− DCs to improve vaccine-induced humoral immunity 
We utilized various human pathogenic antigens such as Y. pestis LcrV, human immunodeficiency virus 
(HIV) Gag, and hepatitis B surface antigen (HBsAg) to validate the increased humoral immune responses 
delivered by CD8α− DC-primed Tfh cells in respect to improved vaccine strategy. For each pathogen, 
effective vaccines are not available and long-term protective humoral responses are required and. Firstly, 
with V antigen, only CD8α− DC targeting induced substantial numbers of anti-V IgM ASCs in the lymph 
nodes, which were effectively isotype-switched to IgG1 (Figure 12-13A). In the spleen, we observed 
similar observation where anti-V IgM ASCs were detected as early as day 3, successfully isotype-
switched to IgG1 at day 5, and later migrated into the bone marrow (Figures 12-13B and C). In contrast, 
we observed inefficacy of targeting CD8α+ DCs against V antigen in inducing anti-V ASCs in all 
lymphoid organs analyzed (Figures 12-13A−C). Overall we observed higher anti-V antibody titers 
including IgG2a isotype in the CD8α− DC targeted group as well (Figure 12-14A). In addition, data 
demonstrating significantly enhanced numbers of anti-V ASCs 6 months after the immunization explain 
the efficacy of targeting CD8α− DCs in the induction of long-term humoral immune responses (Figure 
12-13D). 
Secondly, we utilized DC subset targeting antibodies conjugated with HIV Gagp24 (Gag) in 
order to further validate that increased humoral immune responses induced by CD8α− DCs are not limited 
to V protein, and observed consistent enhancement in anti-Gag ASCs and antibody titers from the CD8α− 
DC targeted group (Figure 12-13E; Figure 12-14B). Thirdly, we utilized purified CD8α− DCs to increase 
humoral immune responses against HBsAg, the immunogen of hepatitis B vaccine. Data again showed 
the up-regulated ICOS expression on the CD4
+
 T cells induced by CD8α− DCs (Figure 2-15) as well as 
significantly enhanced number of anti-HBsAg ASCs following adoptive transfer of the CD8α− DC-
induced CD4
+
 T cells with naïve CD19
+
 B cells into RAG-1-deficient mice (Figure 2-13F). These data 
clearly show the efficacy of the CD8α− DC subset in inducing effective humoral immune responses via 
functional Tfh cell priming. 
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2.4. Discussion 
 
Many studies have reported the importance of DCs in priming Tfh cells, but little is known about detail 
mechanisms by which DC subset primes the initial commitment of antigen-specific CD4
+
 T cells into Tfh 
cells. In this study, our data explain important cellular and molecular mechanisms controlled by CD8α− 
DCs to prime Tfh cell differentiation, enhancing Tfh cell dependent humoral immune responses. We also 
here provide the rationale for targeting the distinct CD8α− DC subset to provoke efficient humoral 
immune responses against various human pathogenic antigens. 
Our study revealed unexplored intrinsic feature differences between the two DC subsets in priming Tfh 
cell differentiation. Of particular, our data demonstrate that the highly enhanced non-canonical NF-κB 
signaling pathway increases the expression levels of ICOSL and OX40L on CD8α− DCs, thereby 
launching a molecular mechanism of distinct DC subset-derived Tfh cell differentiation. We observed that 
such intrinsic features or capability of CD8α− DCs in inducing Tfh cells are not limited to a specific 
stimulus. One previous study reported that ICOSL/ICOS signaling during DC-T cell priming instructs 
Bcl6 expression, leading to increase CXCR5 expression on CD4
+
 T cells and thus determine the early 
bifurcation between Tfh cells and other effector Th cell developments (Choi et al., 2011). However, it has 
not been studied that the distinct CD8α− DC subset enhances ICOS signals to promote Tfh cell induction. 
Interestingly, our study also shows that both ICOSL and OX40L molecules expressed on CD8α− DCs have 
critical roles in promoting ICOS signals of Tfh cells. Considering one previous study suggesting the 
important role of OX40L on CD11c
+
 DCs for CD4
+
 T cells to migrate into the follicle (Brocker et al., 
1999), and another study reporting that OX40 stimulation could overcome the impaired migration of 
CD4
+
 T cells into B cell follicles, initially caused by lack of CD40 on DCs (Fillatreau and Gray, 2003), it 
is conceivable that the increased OX40L expression on CD8α− DCs may also be importantly involved in 
such molecular hierarchy from ICOS to Bcl6 to CXCR5, which eventually help the migration of Tfh cells 
into B cell follicles. Based on the data we presented here that the expressions of ICOSL and OX40L were 
enhanced through the non-canonical NF-kB signaling pathway in CD8α− DCs and the blocking of either 
ICOSL or OX40L critically reduced the ability of CD8α− DCs in inducing Tfh cells in vivo, the Tfh cell 
induction efficiency by the CD8α− DC subset is delivered by its bona fide intrinsic property. 
Because the CD4
+
 T cells primed by CD8α+ DCs highly expressed T-bet and a number of previous reports 
showed the efficacy of targeting CD8α+ DCs in inducing of IFN-γ secreting Th1 cells (Do et al., 2010, 
Trumpfheller et al., 2012), we hypothesize that the highly activated JNK expression is involved in 
inducing Th1 rather than in Tfh cell. However, further studies are necessary to confirm if CD8α+ DCs 
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negatively regulate Tfh dependent-humoral immunity via highly expressed PDL1/L2 molecules and JNK 
signaling.  
Beside the mechanisms we discovered, there are known possibilities such as the differences in antigen 
processing in vivo (Dudziak et al., 2007), prolonged antigen presentation (Deenick et al., 2010, Lahoud et 
al., 2011), or extrafollicular B cell activation (Chappell et al., 2012) of DC subsets could be involved in 
Tfh cell differentiation. In addition, as reported by previous studies that CD14
+
 dermal DCs (Klechevsky 
et al., 2008), late activator antigen-presenting cells (Yoo et al., 2012), or monocyte-derived DCs 
(Chakarov and Fazilleau, 2014) have a role in promoting Tfh cell induction, we believe that Tfh cell 
induction may be dependent on the type of the immune responses or antigen provided. Further 
investigations are necessary to understand how various DC subsets are involved in inducing Tfh cells 
interplaying with each other in vivo within lymphoid organs, which leads us to better appreciate diverse 
physiological functions of DC subsets. One previous study showed that DCs were a potent inducer of 
Bcl6 in naïve CD4
+
 T cells utilizing peptide-pulsed bone marrow derived DCs, but such DC-restricted 
peptide immunization was not able to induce potent GCs and induce lower PD1 expression on Tfh cells 
than the soluble protein immunization (Baumjohann et al., 2011). In addition, when antigens were given 
to only DCs by using CD11c/Aß
b
 mice, there was sufficient initiation of Tfh cell differentiation, but these 
Tfh cells were not able to produce IL-21, thereby requiring additional helps from cognate B cells for full 
effector function (Goenka et al., 2011). In contrast, our CD8α− DC targeting strategy demonstrated that 
immunization with around 1.6 µg ovalbumin could efficiently induce Tfh cells as well as Tfh cell-
dependent humoral immune responses even more than those from the group immunized with 500 µg 
soluble OVA protein, supporting the efficacy of targeting CD8α− DCs in inducing fully functional Tfh 
cells in vivo. 
The involvement of Tfh cells in human diseases was recently reported. A study demonstrated substantial 
expansion of HIV-specific Tfh cells in chronic HIV-infected patients explaining hyper-secreted IgG seen 
in them (Lindqvist et al., 2012). Another study also showed that the expanded Tfh cells in HIV-infected 
patients provided inefficient help to B cells due to the negative regulatory role of PDL1/L2 molecules 
(Cubas et al., 2013). Thus, based on recent studies on HIV vaccine by recruiting Tfh cells (Streeck et al., 
2013), the understanding of cellular and molecular mechanisms involved in Tfh cell initiation and 
differentiation is crucial to develop efficient vaccines and to improve therapeutic approaches. Our study 
clearly supports the value of CD8α− DCs in enhancing humoral immune responses against various human 
pathogenic antigens. In particular, we utilized CD8α− DCs to enhance the number of ASCs specific to 
HBsAg, the immunogen of currently available hepatitis B. Although the current hepatitis B vaccine is 
very effective, 5~15% of vaccinated patients fail to develop humoral immune responses (Coursaget et al., 
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1986, Hadler et al., 1986). CD8α− DC targeting antibody conjugated with HBsAg would be utilized as an 
alternative for hepatitis B vaccine non-responders. Additionally, in our previous study, successful 
protection against virulent Y. pestis pneumonic plague was observed as we targeted CD8α− DCs with V 
protein, of which protection efficacy was mainly delivered via the increased anti-V titers (Do et al., 2010), 
which strongly supports our current study in designing efficient pneumonic plague vaccine by targeting 
CD8α− DCs. Therefore, the CD8α− DC subset has great potential to be utilized as a preferential target for 
developing vaccine efficacy in various humoral immunity related diseases. 
In conclusion, our study provide insightful facts on how myeloid DC subsets affect Tfh cell fate; it may 
not be a purely stochastic event as previously suggested (Deenick et al., 2011, Vinuesa and Cyster, 2011, 
Ballesteros-Tato and Randall, 2013) but instead, the CD8α− DC subset has a selective force to prime the 
initial commitment of Tfh cells. Our study revealed unknown mechanisms involved in Tfh cell 
differentiation by the DC subsets, and we believe that our findings along with future efforts to discover 
human DC subset counterpart of CD8α− DCs will develop efficient vaccines delivering improved quality 
and quantity of humoral immune responses. 
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Figure 2-1. CD8α− DCs induce Tfh cell-dependent antibody secreting cells. (A and B) Naive C57BL6 
(B6) (A) or BALB/c (BC) (B) mice were immunized intraperitoneally (i.p.) with PBS, 
monoclonal antibody (mAb) + poly (I:C) (adjuvant only), 
+
 DC targeting), or 
− 
DC targeting) conjugated mAbs in the presen At 
each indicated time point, spleen or bone marrow cells were prepared and anti-V IgG antibody secreting 
cells (ASCs) were analyzed. (C and D) CXCR5 KO, SAP KO, IL-21R KO (C), IL-12p40 KO, IL-4R KO 
(D), or naïve B6 or BC mi
+
 DC targeting) or 
− 
 
Two weeks after the immunization, spleen cells were prepared and anti-V IgG ASCs were analyzed. *** 
P < 0.001. All data represent mean ± s.d. of three or more independent experiments (A−D, n=3 per group). 
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Figure 2-2. CD8α− DCs efficiently induce Tfh cells in vivo. (A−G) OVA specific 
DO11.10
+
Thy1.1
+
CD4
+
 T cells were adoptively transferred to naive Thy1.2
+ 
BALB/c mice at day -1, and 
were immunized subcutaneously (s.c.) with PBS, soluble OVA protein (OVA protein), 
(CD8α+ − DC targeting) conjugated mAbs in the presence of poly 
(I:C) (A−C) or LPS (D−F) at day 0. At each indicated time point after the immunization, lymph node 
cells were prepared and Tfh cells gated from the DO11.10
+
CD4
+
CD44
+ 
T cells were analyzed. (A and D) 
Representative FACS plots of CXCR5
+
PD1
+
, CXCR5
+
Bcl6
+
, or
 
CXCR5
+
IL-21
+
 Tfh cells. (B and E) 
Percentages (%) of Tfh cells described in (A) and (D), respectively. (C and F) The number (#) of Tfh cells 
described in (A) and (D), respectively. (G) The total number of DO11.10
+
CD4
+ 
T cells. Data represent 
mean ± s.e.m. of three or more independent experiments (B and C, E−G). * P < 0.05, ** P < 0.01, *** P 
< 0.001. (A−G, n=3-4 per group). 
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Figure 2-3. Induction of Tfh cells by CD8α− DCs in vivo. (A−F) OVA specific DO11.10+Thy1.1+CD4+ 
T cells were adoptively transferred to naive Thy1.2
+ 
BALB/c mice at day -1, and were immunized s.c. 
with PBS, OVA protein, 
+
 
−
 DC targeting) 
conjugated mAbs in the presence of poly (I:C) at day 0. At each indicated time point after the 
immunization, lymph node (A) or spleen cells (B−F) were prepared and Tfh cells gated from the 
DO11.10
+
CD4
+
CD44
+ 
T cells were analyzed. (A) Gating strategy of CXCR5
+
PD1
+
 Tfh or isotype control 
B) Representative FACS plots of 
CXCR5
+
PD1
+
, CXCR5
+
Bcl6
+
, or
 
CXCR5
+
IL-21
+
 Tfh cells. (C) Percentages (%) of Tfh cells described in 
(B). (D) The number (#) of Tfh cells described in (B). (E) The total number of DO11.10
+
CD4
+ 
T cells. (F) 
The number of Tfh cells normalized by the total number of DO11.10
+
CD4
+ 
T cells. Data represent mean ± 
s.e.m. of three or more independent experiments (B−F). * P < 0.05, ** P < 0.01, *** P < 0.001. (A−F, 
n=3-4 per group). 
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Figure 2-4. Induction of Tfh cells by CD8α− DCs in vivo. (A−H) OVA specific DO11.10+Thy1.1+CD4+ 
T cells were adoptively transferred to naive Thy1.2
+ 
BALB/c mice at day -1, and were immunized s.c. 
with PBS, OVA protein, 
+
 
−
 DC targeting) 
conjugated mAbs in the presence of LPS at day 0. At each indicated time point after the immunization, 
lymph node (A and G and H) or spleen cells (B−H) were prepared and Tfh cells gated from the 
DO11.10
+
CD4
+
CD44
+ 
T cells were analyzed. (A) Gating strategy of CXCR5
+
PD1
+
 Tfh or isotype control 
B) Representative FACS plots of 
CXCR5
+
PD1
+
, CXCR5
+
Bcl6
+
, or
 
CXCR5
+
IL-21
+
 Tfh cells. (C) Percentages (%) of Tfh cells described in 
(B). (D) The number (#) of Tfh cells described in (B). (E) The total number of DO11.10
+
CD4
+ 
T cells. (F) 
The number of Tfh cells normalized by the total number of DO11.10
+
CD4
+ 
T cells. (G and H) The 
number of CD4
+
IFN-γ+ (G) or CD4+IL-4+ (H) T cells obtained either from the lymph nodes (LN) or the 
spleen (SP). Data represent mean ± s.e.m. of three or more independent experiments (B−H). * P < 0.05, 
** P < 0.01, *** P < 0.001. (A−H, n=3-4 per group). 
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Figure 2-5. CD8α− DCs induce Tfh cells in vitro. (A−G) OT-II OVA specific Vα2+CD4+ T cells were 
co-cultured with each DC subset in the presence of OVA peptide (323-339) with poly (I:C) (A−C and G), 
LPS (D and E), or LPS, Flagellin or R848 (F). At each indicated time point after the co-culture, 
Vα2+CD4+CD44+ T cells were analyzed. (A)  Representative histograms of ICOS expression. (B) 
Median fluorescence intensity (MFI) of three independent experiments described in (A), mean ± s.e.m. (C) 
The relative mRNA expression of Bcl6, c-Maf or T-bet. (D and E) MFI of CXCR5, ICOS (D) and Bcl6 
(E). (F) IL-21 production. (G) Three days after the co-culture, Vα2+CD4+CD44+ T cells were sorted and 
adoptively transferred together with naïve CD19
+
 B cells to RAG-1-deficient mice. Fourteen days after 
the boost immunization with OVA protein, spleen cells were prepared and anti-IgG ASCs were analyzed 
(n=2 per group). * P < 0.05, ** P < 0.01, *** P < 0.001. Data represent mean ± s.e.m of three or more 
(C−F) or two (G) independent experiments. 
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Figure 2-6. Induction of Tfh cells by CD8α− DCs in vitro. OT-II OVA specific Vα2+CD4+ T cells were 
co-cultured with each DC subset in the presence of OVA peptide (323-339) and poly (I:C). At each 
indicated time point after the co-culture, Vα2+CD4+CD44+ T cells were analyzed. (A) Relative mRNA 
expressions of Icos and Sap. * P < 0.05, *** P < 0.001. Data represent mean ± s.e.m. of three 
independent experiments. (B) Proliferation of OT-II OVA specific Vα2+CD4+ T cells analyzed by CFSE 
dilution assay. Data are representative of three independent experiments. 
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Figure 2-7. CD8α− DCs enhance the formation of GC B cells and antibody titers. (A−D) OVA 
specific DO11.10
+
Thy1.1
+
CD4
+
 T cells were adoptively transferred to naive Thy1.2
+ 
BALB/c mice at day 
-1, and were immunized s.c. with PBS, OVA protein, 
+
 DC targeting), or 
−
 DC targeting) conjugated mAbs in the presence of poly (I:C) (A−C) or LPS (D) 
at day 0. At each indicated time point after the immunization, spleen cells (A and B) or sera (C and D) 
were prepared for analysis. (A) Representative FACS plots of GL7
+
FAS
+ 
GC B cells gated from 
CD19
+
IgD
− 
splenocytes. (B) Data represent mean ± s.e.m. of four independent experiments described in 
(A). (C) ELISA analyses of OVA−specific serum IgM or IgG antibodies. (D) Ten days after the 
immunization, each group was re-immunized with NP16-OVA (day 0). ELISA of NP-specific serum IgG 
antibodies (NP8/NP30). * P < 0.05, ** P < 0.01, *** P < 0.001. Data represent mean ± s.e.m. of four (C 
and D) independent experiments. (A−D, n=3-4 per group).  
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Figure 2-8. GC B cell and Germinal Center formation induced by CD8α− DCs. (A−C) OVA specific 
DO11.10
+
Thy1.1
+
CD4
+
 T cells were adoptively transferred to naive Thy1.2
+ 
BALB/c mice at day -1, and 
were immunized s.c. with PBS, OVA protein, 
+
 DC targeting), or DCIR2:OVA 
(CD8α− DC targeting) conjugated mAbs in the presence of LPS at day 0. 5 days after the immunization, 
spleen cells were prepared for analysis. (A) Representative FACS plots of GL7
+
FAS
+ 
GC B cells gated 
from CD19
+
IgD
− 
splenocytes. (n=4 per group). (B) Data represent mean ± s.e.m. of five independent 
experiments described in (A). (C) Immunohistochemical staining of spleen sections from each indicated 
group (IgD, blue; PNA, green). Data are representative of three or more independent experiments. (n >10 
per group). 
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Figure 2-9. The increased number of Tfh cells was induced by the enhanced expressions of ICOSL 
and OX40L on CD8α− DCs. (A and B) Sorted DC subsets were stimulated either with poly (I:C) (A) or 
LPS (B) for 0, 12, 24 hours in vitro. Representative histograms of ICOSL and OX40L. MFIs represent 
mean ± s.e.m. of three independent experiments. (C) OT-II OVA specific Vα2+CD4+ T cells were co-
cultured with each DC subset with OVA peptide (323-339) and LPS in the presence of ICOSL or OX40L 
blocking (αICOSL or αOX40L) mAbs or Isotype mAbs (Iso Ab) for 3 days. MFI of CXCR5 was analyzed 
from three independent experiments, mean ± s.e.m. (D and E) OVA specific DO11.10
+
Thy1.1
+
CD4
+
 T 
cells were adoptively transferred to naive Thy1.2
+ 
BALB/c mice at day -1, and were immunized s.c. with 
either 
+
 
−
 DC targeting) conjugated mAbs in 
the presence of LPS at day 0. ICOSL or OX40L blocking mAbs (αICOSL or αOX40L) or Isotype mAbs 
(Iso Ab) were injected intravenously (i.v.) to the immunized mice at day 0 and 2. Four days after the 
immunization, lymph nodes cells were prepared. MFI of CXCR5 (D) and the number of CXCR5
+
PD1
+
, 
CXCR5
+
Bcl61
+
, or CXCR5
+
IL-21
+
 Tfh cells (E) were analyzed from three independent experiments, 
mean ± s.e.m. (n=4 per group). * P < 0.05, ** P < 0.01, *** P < 0.001.  
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Figure 2-10. Induction of Tfh cells by the enhanced expressions of ICOSL and OX40L on CD8α− 
DCs. (A and B) Sorted DC subsets were stimulated either with poly (I:C) (A) or LPS (B) for 0, 12, 24 
hours in vitro. Representative histograms of PDL1 and PDL2. MFIs represent mean ± s.e.m. of three 
independent experiments. (C) OT-II OVA specific Vα2+CD4+ T cells were co-cultured with each DC 
subset with OVA peptide (323-339) and poly (I:C) in the presence of ICOSL or OX40L blocking 
(αICOSL or αOX40L) mAbs or Isotype mAbs (Iso Ab) for 3 days. MFI of ICOS was analyzed from three 
independent experiments, mean ± s.e.m. (D) OVA specific DO11.10
+
Thy1.1
+
CD4
+
 T cells were 
adoptively transferred to naive Thy1.2
+ 
BALB/c mice at day -1, and were immunized s.c. with either 
+
 
−
 DC targeting) conjugated mAbs in the 
presence of LPS at day 0. ICOSL or OX40L blocking mAbs (αICOSL or αOX40L) or Isotype mAbs (Iso 
Ab) were injected intravenously (i.v.) to the immunized mice at day 0 and 2. Four days after the 
immunization, spleen cells were prepared. The number of CXCR5
+
PD1
+
, CXCR5
+
Bcl61
+
, or CXCR5
+
IL-
21
+
 Tfh cells were calculated from two or three independent experiments, mean ± s.e.m. (n=4 per group). 
* P < 0.05, ** P < 0.01, *** P < 0.001. 
 
 
 
 
 
 
 
 
61 
 
 
62 
 
Figure 2-11. CD8α− DCs induce high expressions of ICOSL and OX40L via enhanced non-canonical 
NF-κB signaling pathway. (A and B) Sorted DC subsets were stimulated with either poly (I:C) or αCD40 
for 2 hours in vitro followed by western blot analysis of non-canonical NF-κB-(A) or MAPK- (B) 
pathway related molecules. Phosphorylation (p), Total (T). (C) ChIP-PCR shows percent (%) input of p52 
upstream of Icosl and Ox40l in the DC subsets in the absence or the presence of stimulation. Data are 
representative of three (A and B) or two (C) independent experiments (mean ± s.d.). (D) The two DC 
subsets were treated with either DMSO (vehicle) or a NIK inhibitor (αNIK) for 12 hours in the presence 
of poly (I:C) and the MFI of ICOSL or OX40L was analyzed. Data represent mean ± s.e.m. of three 
(ICOSL) or two (OX40L) independent experiments. * P < 0.05, ** P < 0.01, *** P < 0.001. 
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Figure 2-12. Western blot and chip analysis. (A) Quantitative and relative density of western blot 
analyses described in Figure 6A and 6B represent mean ± s.e.m. of three independent experiments. 
Phosphorylation (p), Total (T). (B) Predicted NF-κB complex binding site on the upstream regions of 
OX40L and ICOSL gene promoter. The predicted NF-κB complex binding sites were analyzed by NF-κB 
binding motif computation method (Britanova et al., 2008). Six major areas of NF-κB complex binding 
sites (-50, -500, -1000, -1700, -3200 and -3500) were identified on the upstream region of OX40L and 
three major areas of NF-κB complex binding sites (-1300, -3000 and -5000) were identified on the 
upstream region of ICOSL. Red dotted lines are the sites where are confirmed by Chip-qPCR. (C) ChIP-
PCR shows percent (%) input of p52 upstream of Gapdh (negative control) and Ccl2 (positive control) in 
the two DC subsets in the absence or the presence of stimulation. Data are representative of two 
independent experiments, mean ± s.d. 
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Figure 2-13. CD8α− DCs enhance Tfh cell dependent-humoral immune responses against various 
human antigens. (A−C + DC targeting) 
(CD8α− 
At each indicated time point after the immunization, cells from the lymph nodes (LN) (A), spleen (SP) 
(B), or the bone marrow (BM) (C) were prepared and anti-V (IgM or IgG1) ASCs were analyzed. (D) 
BALB/c mice were primed and boosted with PBS, F1-
(CD8α+ − DC targeting) conjugated mAbs in the presence of poly 
(I:C). Six months later, bone marrow cells were prepared and anti-V ASCs were analyzed. (E) B6 mice 
+
 DC 
−
 DC targeting) conjugated mAbs in the presence of poly (I:C). 
Two weeks after the boost, bone marrow cells were prepared and anti-gagp24 ASCs cells were analyzed. 
(F) Naive CD4
+ 
T cells co-cultured with each DC subset in the presence of poly (I:C) for 3 days were 
isolated and then adoptively transferred together with naïve CD19
+
 B cells to RAG-1-deficient mice. 
Fourteen days after the boost immunization with soluble HBsAg, spleen cells were prepared and anti-IgG 
HBsAg ASCs were analyzed. ** P < 0.01, *** P < 0.001. All data represent mean ± s.d. of three or more 
independent experiments (A−F, n=3 per group). 
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Figure 2-14. Induction of Tfh cell dependent-humoral immune responses by CD8α− DCs. (A) ELISA 
analyses of V-specific serum antibodies collected from the mice described in Figure 7A. (B) ELISA of 
Gag-specific serum antibodies collected from the mice described in Figure 7E. * P < 0.05, ** P < 0.01, 
*** P < 0.001. All data represent mean ± s.d. of three or more independent experiments (A and B, n=3 
mice per group). 
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Figure 2-15. ICOS expression on the CD4
+
 T cells induced by the two DC subsets with HBsAg. 
Representative histograms of the expression of ICOS on the CD4
+ 
T cells induced by the two DC subsets 
in the presence of HBsAg. Data are representative of three independent experiments. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
69 
 
References 
 
AKIBA, H., TAKEDA, K., KOJIMA, Y., USUI, Y., HARADA, N., YAMAZAKI, T., MA, J., TEZUKA, 
K., YAGITA, H. & OKUMURA, K. 2005. The role of ICOS in the CXCR5+ follicular B helper T 
cell maintenance in vivo. J Immunol, 175, 2340-8. 
BALLESTEROS-TATO, A. & RANDALL, T. D. 2013. Priming of T follicular helper cells by dendritic 
cells. Immunol Cell Biol. 
BAUMJOHANN, D., OKADA, T. & ANSEL, K. M. 2011. Cutting Edge: Distinct waves of BCL6 
expression during T follicular helper cell development. J Immunol, 187, 2089-92. 
BAUQUET, A. T., JIN, H., PATERSON, A. M., MITSDOERFFER, M., HO, I. C., SHARPE, A. H. & 
KUCHROO, V. K. 2009. The costimulatory molecule ICOS regulates the expression of c-Maf 
and IL-21 in the development of follicular T helper cells and TH-17 cells. Nat Immunol, 10, 167-
75. 
BREITFELD, D., OHL, L., KREMMER, E., ELLWART, J., SALLUSTO, F., LIPP, M. & FORSTER, R. 
2000. Follicular B helper T cells express CXC chemokine receptor 5, localize to B cell follicles, 
and support immunoglobulin production. J Exp Med, 192, 1545-52. 
BRITANOVA, L. V., MAKEEV, V. J. & KUPRASH, D. V. 2008. In vitro selection of optimal RelB/p52 
DNA-binding motifs. Biochem Biophys Res Commun, 365, 583-8. 
BROCKER, T., GULBRANSON-JUDGE, A., FLYNN, S., RIEDINGER, M., RAYKUNDALIA, C. & 
LANE, P. 1999. CD4 T cell traffic control: in vivo evidence that ligation of OX40 on CD4 T cells 
by OX40-ligand expressed on dendritic cells leads to the accumulation of CD4 T cells in B 
follicles. Eur J Immunol, 29, 1610-6. 
CANNONS, J. L., QI, H., LU, K. T., DUTTA, M., GOMEZ-RODRIGUEZ, J., CHENG, J., WAKELAND, 
E. K., GERMAIN, R. N. & SCHWARTZBERG, P. L. 2010. Optimal germinal center responses 
require a multistage T cell:B cell adhesion process involving integrins, SLAM-associated protein, 
and CD84. Immunity, 32, 253-65. 
CHAKAROV, S. & FAZILLEAU, N. 2014. Monocyte-derived dendritic cells promote T follicular helper 
cell differentiation. EMBO Mol Med, 6, 590-603. 
CHAPPELL, C. P., DRAVES, K. E., GILTIAY, N. V. & CLARK, E. A. 2012. Extrafollicular B cell 
activation by marginal zone dendritic cells drives T cell-dependent antibody responses. J Exp 
Med, 209, 1825-40. 
70 
 
CHOI, Y. S., KAGEYAMA, R., ETO, D., ESCOBAR, T. C., JOHNSTON, R. J., MONTICELLI, L., LAO, 
C. & CROTTY, S. 2011. ICOS receptor instructs T follicular helper cell versus effector cell 
differentiation via induction of the transcriptional repressor Bcl6. Immunity, 34, 932-46. 
COOPE, H. J., ATKINSON, P. G., HUHSE, B., BELICH, M., JANZEN, J., HOLMAN, M. J., KLAUS, G. 
G., JOHNSTON, L. H. & LEY, S. C. 2002. CD40 regulates the processing of NF-kappaB2 p100 
to p52. EMBO J, 21, 5375-85. 
COURSAGET, P., YVONNET, B., CHOTARD, J., SARR, M., VINCELOT, P., N'DOYE, R., DIOP-
MAR, I. & CHIRON, J. P. 1986. Seven-year study of hepatitis B vaccine efficacy in infants from 
an endemic area (Senegal). Lancet, 2, 1143-5. 
CROTTY, S. 2011. Follicular helper CD4 T cells (TFH). Annu Rev Immunol, 29, 621-63. 
CUBAS, R. A., MUDD, J. C., SAVOYE, A. L., PERREAU, M., VAN GREVENYNGHE, J., METCALF, 
T., CONNICK, E., MEDITZ, A., FREEMAN, G. J., ABESADA-TERK, G., JR., JACOBSON, J. 
M., BROOKS, A. D., CROTTY, S., ESTES, J. D., PANTALEO, G., LEDERMAN, M. M. & 
HADDAD, E. K. 2013. Inadequate T follicular cell help impairs B cell immunity during HIV 
infection. Nat Med, 19, 494-9. 
CUCAK, H., YRLID, U., REIZIS, B., KALINKE, U. & JOHANSSON-LINDBOM, B. 2009. Type I 
interferon signaling in dendritic cells stimulates the development of lymph-node-resident T 
follicular helper cells. Immunity, 31, 491-501. 
DEENICK, E. K., CHAN, A., MA, C. S., GATTO, D., SCHWARTZBERG, P. L., BRINK, R. & 
TANGYE, S. G. 2010. Follicular helper T cell differentiation requires continuous antigen 
presentation that is independent of unique B cell signaling. Immunity, 33, 241-53. 
DEENICK, E. K., MA, C. S., BRINK, R. & TANGYE, S. G. 2011. Regulation of T follicular helper cell 
formation and function by antigen presenting cells. Curr Opin Immunol, 23, 111-8. 
DEN HAAN, J. M., LEHAR, S. M. & BEVAN, M. J. 2000. CD8(+) but not CD8(-) dendritic cells cross-
prime cytotoxic T cells in vivo. J Exp Med, 192, 1685-96. 
DO, Y., KOH, H., PARK, C. G., DUDZIAK, D., SEO, P., MEHANDRU, S., CHOI, J. H., CHEONG, C., 
PARK, S., PERLIN, D. S., POWELL, B. S. & STEINMAN, R. M. 2010. Targeting of LcrV 
virulence protein from Yersinia pestis to dendritic cells protects mice against pneumonic plague. 
Eur J Immunol, 40, 2791-6. 
DUDZIAK, D., KAMPHORST, A. O., HEIDKAMP, G. F., BUCHHOLZ, V. R., TRUMPFHELLER, C., 
YAMAZAKI, S., CHEONG, C., LIU, K., LEE, H. W., PARK, C. G., STEINMAN, R. M. & 
NUSSENZWEIG, M. C. 2007. Differential antigen processing by dendritic cell subsets in vivo. 
Science, 315, 107-11. 
71 
 
FILLATREAU, S. & GRAY, D. 2003. T cell accumulation in B cell follicles is regulated by dendritic cells 
and is independent of B cell activation. J Exp Med, 197, 195-206. 
GOENKA, R., BARNETT, L. G., SILVER, J. S., O'NEILL, P. J., HUNTER, C. A., CANCRO, M. P. & 
LAUFER, T. M. 2011. Cutting edge: dendritic cell-restricted antigen presentation initiates the 
follicular helper T cell program but cannot complete ultimate effector differentiation. J Immunol, 
187, 1091-5. 
GOODNOW, C. C., VINUESA, C. G., RANDALL, K. L., MACKAY, F. & BRINK, R. 2010. Control 
systems and decision making for antibody production. Nat Immunol, 11, 681-8. 
HADLER, S. C., FRANCIS, D. P., MAYNARD, J. E., THOMPSON, S. E., JUDSON, F. N., 
ECHENBERG, D. F., OSTROW, D. G., O'MALLEY, P. M., PENLEY, K. A., ALTMAN, N. L. & 
ET AL. 1986. Long-term immunogenicity and efficacy of hepatitis B vaccine in homosexual men. 
N Engl J Med, 315, 209-14. 
HAMS, E., MCCARRON, M. J., AMU, S., YAGITA, H., AZUMA, M., CHEN, L. & FALLON, P. G. 
2011. Blockade of B7-H1 (programmed death ligand 1) enhances humoral immunity by 
positively regulating the generation of T follicular helper cells. J Immunol, 186, 5648-55. 
HAYNES, N. M., ALLEN, C. D., LESLEY, R., ANSEL, K. M., KILLEEN, N. & CYSTER, J. G. 2007. 
Role of CXCR5 and CCR7 in follicular Th cell positioning and appearance of a programmed cell 
death gene-1high germinal center-associated subpopulation. J Immunol, 179, 5099-108. 
HU, H., WU, X., JIN, W., CHANG, M., CHENG, X. & SUN, S. C. 2011. Noncanonical NF-kappaB 
regulates inducible costimulator (ICOS) ligand expression and T follicular helper cell 
development. Proc Natl Acad Sci U S A, 108, 12827-32. 
IYODA, T., SHIMOYAMA, S., LIU, K., OMATSU, Y., AKIYAMA, Y., MAEDA, Y., TAKAHARA, K., 
STEINMAN, R. M. & INABA, K. 2002. The CD8+ dendritic cell subset selectively endocytoses 
dying cells in culture and in vivo. J Exp Med, 195, 1289-302. 
JOHNSTON, R. J., POHOLEK, A. C., DITORO, D., YUSUF, I., ETO, D., BARNETT, B., DENT, A. L., 
CRAFT, J. & CROTTY, S. 2009. Bcl6 and Blimp-1 are reciprocal and antagonistic regulators of 
T follicular helper cell differentiation. Science, 325, 1006-10. 
KAPLAN, M. H., SCHINDLER, U., SMILEY, S. T. & GRUSBY, M. J. 1996. Stat6 is required for 
mediating responses to IL-4 and for development of Th2 cells. Immunity, 4, 313-9. 
KLECHEVSKY, E., MORITA, R., LIU, M., CAO, Y., COQUERY, S., THOMPSON-SNIPES, L., 
BRIERE, F., CHAUSSABEL, D., ZURAWSKI, G., PALUCKA, A. K., REITER, Y., 
BANCHEREAU, J. & UENO, H. 2008. Functional specializations of human epidermal 
Langerhans cells and CD14+ dermal dendritic cells. Immunity, 29, 497-510. 
72 
 
LAHOUD, M. H., AHMET, F., KITSOULIS, S., WAN, S. S., VREMEC, D., LEE, C. N., PHIPSON, B., 
SHI, W., SMYTH, G. K., LEW, A. M., KATO, Y., MUELLER, S. N., DAVEY, G. M., HEATH, W. 
R., SHORTMAN, K. & CAMINSCHI, I. 2011. Targeting antigen to mouse dendritic cells via 
Clec9A induces potent CD4 T cell responses biased toward a follicular helper phenotype. J 
Immunol, 187, 842-50. 
LINDQVIST, M., VAN LUNZEN, J., SOGHOIAN, D. Z., KUHL, B. D., RANASINGHE, S., KRANIAS, 
G., FLANDERS, M. D., CUTLER, S., YUDANIN, N., MULLER, M. I., DAVIS, I., FARBER, D., 
HARTJEN, P., HAAG, F., ALTER, G., SCHULZE ZUR WIESCH, J. & STREECK, H. 2012. 
Expansion of HIV-specific T follicular helper cells in chronic HIV infection. J Clin Invest, 122, 
3271-80. 
MA, C. S., DEENICK, E. K., BATTEN, M. & TANGYE, S. G. 2012. The origins, function, and 
regulation of T follicular helper cells. J Exp Med, 209, 1241-53. 
MA, C. S., SURYANI, S., AVERY, D. T., CHAN, A., NANAN, R., SANTNER-NANAN, B., DEENICK, 
E. K. & TANGYE, S. G. 2009. Early commitment of naive human CD4(+) T cells to the T 
follicular helper (T(FH)) cell lineage is induced by IL-12. Immunol Cell Biol, 87, 590-600. 
MOSMANN, T. R. & COFFMAN, R. L. 1989. TH1 and TH2 cells: different patterns of lymphokine 
secretion lead to different functional properties. Annu Rev Immunol, 7, 145-73. 
NURIEVA, R. I., CHUNG, Y., HWANG, D., YANG, X. O., KANG, H. S., MA, L., WANG, Y. H., 
WATOWICH, S. S., JETTEN, A. M., TIAN, Q. & DONG, C. 2008. Generation of T follicular 
helper cells is mediated by interleukin-21 but independent of T helper 1, 2, or 17 cell lineages. 
Immunity, 29, 138-49. 
NUSSENZWEIG, M. C., STEINMAN, R. M., WITMER, M. D. & GUTCHINOV, B. 1982. A 
monoclonal antibody specific for mouse dendritic cells. Proc Natl Acad Sci U S A, 79, 161-5. 
QI, H., CANNONS, J. L., KLAUSCHEN, F., SCHWARTZBERG, P. L. & GERMAIN, R. N. 2008. SAP-
controlled T-B cell interactions underlie germinal centre formation. Nature, 455, 764-9. 
RANUNCOLO, S. M., PITTALUGA, S., EVBUOMWAN, M. O., JAFFE, E. S. & LEWIS, B. A. 2012. 
Hodgkin lymphoma requires stabilized NIK and constitutive RelB expression for survival. Blood, 
120, 3756-63. 
REINHARDT, R. L., LIANG, H. E. & LOCKSLEY, R. M. 2009. Cytokine-secreting follicular T cells 
shape the antibody repertoire. Nat Immunol, 10, 385-93. 
SCHAERLI, P., WILLIMANN, K., LANG, A. B., LIPP, M., LOETSCHER, P. & MOSER, B. 2000. CXC 
chemokine receptor 5 expression defines follicular homing T cells with B cell helper function. J 
Exp Med, 192, 1553-62. 
73 
 
SHIN, C., HAN, J. A., KOH, H., CHOI, B., CHO, Y., JEONG, H., RA, J. S., SUNG, P. S., SHIN, E. C., 
RYU, S. & DO, Y. 2015. CD8alpha(-) Dendritic Cells Induce Antigen-Specific T Follicular 
Helper Cells Generating Efficient Humoral Immune Responses. Cell Rep, 11, 1929-40. 
SHORTMAN, K. & LIU, Y. J. 2002. Mouse and human dendritic cell subtypes. Nat Rev Immunol, 2, 151-
61. 
SLIFKA, M. K., MATLOUBIAN, M. & AHMED, R. 1995. Bone marrow is a major site of long-term 
antibody production after acute viral infection. J Virol, 69, 1895-902. 
STREECK, H., D'SOUZA, M. P., LITTMAN, D. R. & CROTTY, S. 2013. Harnessing CD4(+) T cell 
responses in HIV vaccine development. Nat Med, 19, 143-9. 
SUN, S. C. 2011. Non-canonical NF-kappaB signaling pathway. Cell Res, 21, 71-85. 
SWIGGARD, W. J., MIRZA, A., NUSSENZWEIG, M. C. & STEINMAN, R. M. 1995. DEC-205, a 205-
kDa protein abundant on mouse dendritic cells and thymic epithelium that is detected by the 
monoclonal antibody NLDC-145: purification, characterization, and N-terminal amino acid 
sequence. Cell Immunol, 165, 302-11. 
TANGYE, S. G., MA, C. S., BRINK, R. & DEENICK, E. K. 2013. The good, the bad and the ugly - TFH 
cells in human health and disease. Nat Rev Immunol, 13, 412-26. 
TANGYE, S. G. & TARLINTON, D. M. 2009. Memory B cells: effectors of long-lived immune 
responses. Eur J Immunol, 39, 2065-75. 
TRUMPFHELLER, C., LONGHI, M. P., CASKEY, M., IDOYAGA, J., BOZZACCO, L., KELER, T., 
SCHLESINGER, S. J. & STEINMAN, R. M. 2012. Dendritic cell-targeted protein vaccines: a 
novel approach to induce T-cell immunity. J Intern Med, 271, 183-92. 
VINUESA, C. G. & CYSTER, J. G. 2011. How T cells earn the follicular rite of passage. Immunity, 35, 
671-80. 
YOO, J. K., FISH, E. N. & BRACIALE, T. J. 2012. LAPCs promote follicular helper T cell 
differentiation of Ag-primed CD4+ T cells during respiratory virus infection. J Exp Med, 209, 
1853-67. 
 
 
 
 
 
 
 
74 
 
Chapter 3. Intrinsic features of the CD8α− dendritic cell subset in inducing 
functional T follicular helper cells 
 
3.1. Introduction 
 
T follicular helper (Tfh) cells have been identified as the true B cell helper and noted for their competence 
of regulating T cell dependent humoral immune responses (King, 2009, Crotty, 2011, McHeyzer-Williams 
et al., 2012). Once the major role of CXCR5 in Tfh cells was identified, leading its CXCL13 dependent 
migration into the germinal center (GC) (Breitfeld et al., 2000, Schaerli et al., 2000), where they help 
cognate B cells to induce antigen specific antibody responses, several distinct features of Tfh cells, high 
expressions of ICOS and PD1, low expression of CCR7, transcription factor Bcl6, and major cytokine IL-
21 were identified to be distinguished from other CD4
+
 T cell subsets (Ma et al., 2012). In addition, it has 
been reported that Tfh cells are involved in humoral immunity related diseases such as autoimmunity and 
humoral immunodeficiency (Tangye et al., 2013), suggesting understanding the initial induction of Tfh 
cell differentiation is vital and crucial. Although important features of Tfh cells have been identified by 
many researches, how naïve CD4
+
 T cells receive initial signal to differentiate into Tfh cells is not clearly 
understood. 
Dendritic cells (DCs), known as the most potent antigen presenting cell (APC), is the major regulator in inducing 
several CD4
+
 effector T cell subsets (Steinman and Banchereau, 2007). Two major myeloid DC subsets in the 
secondary lymphoid organs such as the lymph nodes and spleen have been identified by the expression of CD8α, 
either CD11c
+CD8α+ DCs which express the endocytic receptor DEC-205 or CD11c+CD8− DCs that express the 
endocytic receptor DCIR2 (Iyoda et al., 2002, Dudziak et al., 2007). We recently reported that the conventional 
CD8α− DC subset specializes in inducing functional Tfh cells both in vitro and in vivo when compared with those 
induced by CD8α+ DCs (Shin et al., 2015). We also demonstrated the importance of ICOSL and OX40L expressed 
on the CD8α− DC subset through the highly increased non-canonical signaling pathway in the induction of 
functional Tfh cells (Shin et al., 2015). However, several important and distinct features such as the proximal 
localization of the two conventional DC subsets to antigen specific CD4
+
 T cells in vivo, potential cytokines secreted 
from the DC subsets and the possible involvement of other APCs, majorly cognate B cells, in inducing Tfh cells 
have not been elucidated. Therefore, the aim of this current study was to investigate the unknown intrinsic features 
of the two conventional DC subsets in the initiation of Tfh cell differentiation by utilizing DC subset targeting 
strategy and isolated DC subsets. In this study, we showed that the localization of the CD8α− DC subset in the 
marginal zone (MZ) bridging channels is closely related to the induction of CXCR5
+
CCR7
low
 Tfh cells in vivo. We 
also demonstrated that that the major source of IL-6 cytokine in inducing Tfh cells is secreted from the antigen 
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specifically activated CD4
+
 T cells induced by CD8α− DCs, and those secreted by the two DC subsets seem minor. 
CD8α− DCs were dominant in inducing Tfh cell dependent humoral immune responses over other antigen presenting 
cells including B cells. We here unveiled the undescribed important intrinsic features of the two DC subsets, 
suggesting the potential of utilizing CD8α− DCs as a therapeutic vaccination tool to modulate T cell dependent 
humoral immune responses. 
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3.2. Experimental procedure 
 
Mice 
Naïve BALB/c (H-2
d
) and C57BL/6 (H-2
b
) mice were purchased from Taconic. OVA antigen specific 
transgenic OT-II and DO11.10 Thy 1.1 mice were purchased from The Jackson Laboratory. All mice 
were maintained under specific pathogen-free conditions and used at 6-8 weeks approved by Ulsan 
National Institute of Science and Technology Institutional Animal Care and Use Committee (approval 
number: UNISTIACUC-12-006-A). 
 
Dendritic cell preparation 
Total number of splenic dendritic cells was increased by Fms-like tyrosine 3 ligand (Flt3L) as previously 
described (Dudziak et al., 2007). In brief, 5 × 10
6 
cells of Flt3L-melanoma cells were subcutaneously (s.c.) 
injected to naïve C57BL/6 mice. After 10-14 days, the expanded splenic CD11c
+
 DCs were enriched with 
positive magnetic-activated cell sorting (MACS; Miltenyi Biotec, GmbH, Bergisch Gladbach, Germany) 
and were further sorted into the two DC subsets, CD3
−
B220
−
CD11c
+
CD8α+ or CD3−B220−CD11c+CD8α− 
DCs by MoFlo XDP (Beckman Coulter, CA, USA). To analyze intrinsic differences in the two DC 
subsets, the DCs were stimulated with either 25 µg poly (I:C) or 100 ng/ml LPS for 0, 12 or 24 hours.  
 
CD4
+
 T cell preparation 
OVA-specific transgenic CD4
+
 T cells from the lymph nodes and the spleen of OT-II or DO11.10 Thy1.1 
mice were negatively isolated using hybridoma supernatant cocktail of rat-anti mouse -CD8 (2.43), -MHC 
class II (T1B120), -Mφ (F4/80), -B220 (RA3-6B2), and -NK cell (NK1.1) antibodies followed by 
depletion with dynabeads sheep anti-rat IgG (Invitrogen, Carlsbad, CA, USA). 
 
CD4
+
 T cell priming by the DC subsets in vitro 
Naive OVA-specific CD4
+
 T (3 × 10
5
) cells purified from OT-II mice were co-cultured either with sorted 
CD8α+ or CD8α− DCs (0.3 × 105 each DCs, 1:10 ratio of DC to T cells) per well in the round bottom 96 
well plate for 3 days in the presence of 25 µg/ml poly (I:C) or 100 ng/ml LPS with 2 µM OVA peptide 
(a.a. 323-339) (Genscript, Piscataway, NJ, USA). Then, cytokines in supernatants were detected by 
ELISA. 
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Induction of CD4
+
 T cells by DC subset targeting in vivo 
Isolated CD4
+
 T cells from DO11.10 Thy 1.1 mice were adoptively transferred (3 × 10
6 
cells per mouse) 
into naïve Thy 1.2
+
 BALB/c mice intravenously (i.v.) at day -1. At day 0, PBS, 500 µg soluble OVA 
protein (endotoxin-free; Seikagaku Corp, Tokyo, Japan), or 5 µg of each distinct DC subset targeting 
monoclonal antibodies (anti-DEC-205 or anti-DCIR2 mAbs) genetically conjugated with OVA protein in 
the presence of 50 µg poly (I:C) were injected via the footpads of the mice. At indicated time points after 
the immunization, single cells from the lymph nodes or the spleen were prepared and analyzed for the 
expression of various molecules by flow cytometry. In some experiments, 5 µg of each distinct DC subset 
targeting mAbs conjugated with OVA protein + 50 µg soluble OVA protein with 50 µg LPS were injected 
via the footpads of the mice. 
 
Production of DC subset-specific targeting antibodies conjugated with OVA protein 
In this study, DC subset-specific targeting antibodies conjugated with OVA protein were used (Do et al., 
2010, Trumpfheller et al., 2012). OVA protein were conjugated either to anti-mouse DEC-205 (for CD8α+ 
DC targeting) mAbs or to anti-mouse DCIR2 (for CD8α− DC targeting) mAbs. All proteins used were free 
of endotoxin (<0.125 endotoxin units/mg) in a Limulus Amebocyte Lysate assay, QCL-1000 (Bio 
Whittaker, Chesterbrook, PA, USA). 
 
ELISA for serum antibodies and cytokines 
High binding ELISA plates (BD Bioscience, San Jose, CA, USA) were coated with 10 µg/ml OVA protein 
overnight at 4 °C. Plates were washed 3 times with PBST (PBS with 0.1% of Tween 20) and blocked with 
PBST-BSA 5% for 1 hour at 37 °C. Serial dilutions of mouse serum were added and incubated for 1 hour 
at 37 °C. Various secondary goat anti-mouse Fc specific antibodies conjugated with horseradish 
peroxidase were added and developed with o-phenylenediamine (Sigma-Aldrich, St. Louis, MO, USA) 
tablets at room temperature for 15 minutes. Data are presented as log antibody titers, with the highest 
dilution showing OD450 >0.1. To detect cytokines in supernatants, we used CBA flex sets (BD Bioscience). 
 
Immunohistochemistry 
Briefly, tissue sections (10 µm) of the spleen were prepared by using Cryotome (Thermo Fisher scientific, 
Waltham, MA, USA) and then fixed with aceton on a slide. For localization images of DCs and T cells, 
samples were stained with BV-421 anti-mouse IgD (BioLegend, San Diego, CA, USA), PE anti-mouse 
DO11.10 (BD Biosciences), and APC anti-mouse DEC205 or 33D1 (BioLegend). Then, the stained 
samples were imaged with FV10i (Olympus, Southend-on-Sea, UK) confocal microscope. 
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Flow cytometry 
Data were acquired by BD FACS Calibur or BD LSRfortessa and analyzed by FlowJo software (TreeStar, 
Ashland, OR, USA), shown on the log scale graph (from 10
1
 to 10
4
 or 10
5
). All bar graph data values 
were shown after subtracting their corresponding isotype values. Median Fluorescence Intensity was 
abbreviated as MFI. Used antibodies in flow cytometry as follows: CD11c (HL3), CD8 (53-6.7), CD3 
(145-2C11), B220 (RA3-6B2), Vα2 (B20.1), Thy1.1 (OX-7), DO11.10 (KJ1-26), CD4 (RM4-5), CD44 
(IM7), CXCR5 (2G8), Bcl6 (K112-91), CCR7 (4B12), CD19 (1D3), IgD (11-26C.2A), FAS (Jo2), GL7 
(GL7), CD80 (16-10A1), CD86(GL1), MHCII (M5/114), Rat IgG2a, κ (R35-95), and Rat IgG2b, κ (A95-
1) were purchased from BD biosciences; PD1 (RMP1-30) and IL-21 (mhalx21) were purchased from 
eBioscience, San Diego, CA, USA. 
 
Intracellular staining 
Cells were stained with anti-mouse DO11.10, CD4, CD44 and CXCR5 for 30 minutes at room 
temperature. Following fixation and permeabilization with Cytofix/Cytoperm kit (BD Biosciences) 
according to the manufacturer’s protocol, the cells were stained for intracellular Bcl6 or IL-21 along with 
their isotypes for 25 minutes at 4 °C. Data were analyzed by flow cytometry. 
 
Statistics 
Results are expressed as mean ± s.e.m. We used PRISM 4.0 program (GraphPad Prism, La Jolla, CA, 
USA) and performed nonparametric Mann-Whitney U test when appropriate. The P values < 0.05 were 
considered significant. 
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3.3. Results 
 
CD4
+
 T cells primed by CD8α− DCs are localized proximal to CD8α− DCs in the marginal zone (MZ) 
bridging channels 
To specifically deliver ovalbumin (OVA) antigens to each DC subset in vivo, we utilized two DC subset 
targeting monoclonal antibodies (mAbs) genetically conjugated with OVA protein, αDEC-205:OVA (for 
CD8α+ DCs targeting) or αDCIR2:OVA (for CD8α− DCs targeting) mAbs. Then, we observed the 
localizations of each DC subset together with OVA antigen specifically primed DO11.10
+
CD4
+
 T cells by 
each DC subset. We confirmed the distinct locations of the two DC subsets in the spleen; CD8α+ DCs 
predominantly localize in the T cell enriched arear whereas CD8α− DCs localize in the MZ bridging 
channels (Figure 3-1), consistent with the previous report (Dudziak et al., 2007). Interestingly, the CD4
+
 
T cells primed by CD8α− DCs tended to localize in the MZ bridging channels, proximal to the localization 
of the CD8α− DC subset as early as 1 day after the immunization, and 3 and 5 days after the immunization, 
the CD4
+
 T cells induced by CD8α− DCs predominantly localized in the MZ bridging channels. In 
contrast, the CD4
+
 T cells primed by CD8α+ DCs remained in the T cell enriched arear at all-time points 
tested (Figure 3-1). 
 
CD4
+
 T cells primed by CD8α− DCs express high levels of CXCR5 and low levels of CCR7 
Consistent to the previous study (Shin et al., 2015), we here again confirmed that CD8α− DCs efficiently 
induce Tfh cells based on the highly expressed feature factors of Tfh cells such as ICOS, PD1, Bcl6 and 
IL-21 (Figures 3-2A-D; Figures 3-3A-B). Given the fact that pre-Tfh cells up-regulate CXCR5 and 
down-regulate CCR7 to migrate into the inter-follicular region/MZ bridging channels (Hardtke et al., 
2005, Haynes et al., 2007), where the development of Tfh cell initiates (Kerfoot et al., 2011), we 
examined the relations of the expressions of CXCR5 and CCR7 on the antigen specifically activated 
CD44
+
CD4
+
 T cells primed by the two distinct DC subsets. Interestingly, we found high expressions of 
CXCR5 on the CD4
+
 T cells primed by CD8α− DCs compared with those induced by CD8α+ DCs at 5 and 
7 days after the immunization both in the lymph node and the spleen (Figures 3-4A and B), and the 
percentage of CCR7
low
CD4
+
 T cells induced by CD8α− DCs was dramatically increased (Figures 3-4C 
and D), indicating that the pre-Tfh cells primed by CD8α− DCs tend to locate in the MZ bridging channels 
through CXCR5-CXCL13 interaction. In contrast, CXCR5
low
CCR7
high
 CD4
+
 T cells primed by CD8α+ 
DCs remained in the T cell enriched area via CCR7-CCL19/21 interaction (Figures 3-4A-D). Although 
the CD4
+
 T cells induced by CD8α− DCs were slightly more proliferative than those by CD8α+ DCs, the 
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proliferation of CD4
+
 T cells induced by OVA protein was similar to those induced by CD8α+ DCs in vivo 
(Figure 3-5), indicating that the inefficacy of CD8α+ DCs in inducing Tfh cells are not due to the defected 
CD4
+  
T cell proliferation. 
 
IL-6 cytokine level secreted from the two DC subsets is dependent on an adjuvant type 
Despite previous reports showing the significance of interleukin-6 (IL-6) for the induction of Tfh cells 
(Eto et al., 2011, Choi et al., 2013), its source, together with the potential of its secretion from the DC 
subsets, were not clearly reported. In order to investigate the level of IL-6 and other cytokines secreted 
from the two DC subsets, we purified each DC subset, CD3
−
B220
−
CD11c
+CD8α+ DCs or 
CD3
−
B220
−
CD11c
+
CD8α− DCs. Each isolated DC subset was treated either with poly (I:C) or LPS for 12 
or 24 hours in vitro. Unexpectedly, significantly enhanced IL-6 secretion from CD8α+ DCs compared 
with that from CD8α− DCs was observed upon poly (I:C) stimulation (Figure 3-6A). However, in the 
presence of LPS stimulation, the level of IL-6 secretion was comparable between the two DC subsets 12 
hours after the stimulation and its level secreted from CD8α− DCs was higher 24 hours after the 
stimulation (Figure 3-6B). Notably, significantly higher level of IL-6 cytokine secreted from the CD4
+
 T 
cells primed by CD8α− DCs was observed in both poly (I:C) and LPS stimulations (Figure 3-6C), 
demonstrating the minor role of IL-6 secreted from CD8α− DCs in the induction of Tfh cells. We observed 
higher levels of pro-inflammatory cytokines such as IL-1β and TNF-α secreted from CD8α+ DCs both in 
poly (I:C) and LPS stimulations (Figures 3-6A and B). The expression levels of co-stimulator CD80 or 
CD86 and MHCII were similar between the two DC subsets (Figure 3-7). 
 
CD8α− DCs specialize in inducing functional Tfh cells 
It has been reported that CD8α− DCIR2+ DCs have a unique capacity to initiate extra-follicular B cell 
responses via rapid activation of Ag-specific B cells in vivo (Chappell et al., 2012), indicating the 
probability that each DC subset is differentially able to deliver antigens to cognate B cells in the 
induction of T cell dependent and antigen specific humoral immune responses. To examine the effect of 
different antigen accessibility of APCs, majorly B cells, on the induction Tfh cells via DC subset 
targeting, we designed one experiment to provide antigens to all APCs equivalently in the both CD8α+ 
and CD8α− DC targeted groups. When mice were immunized with 5 µg of each DC subset specific 
targeting mAbs conjugated with OVA protein (each immunization contains approximately ~1.6 µg OVA 
protein), 50 µg soluble OVA protein was given together to the mice to ensure that B cells and other APCs 
have equivalent access to antigens. Five days after the immunization, significantly higher percentages of 
CXCR5
+
PD1
+
, CXCR5
+
Bcl6
+
 and CXCR5
+
IL-21
+
 Tfh cells were observed both in the lymph nodes 
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(Figures 3-8A and B) and the spleen (Figures 3-8C and D) from the CD8α− DC targeted group 
compared with those from the CD8α+ DC targeted group. Moreover, we observed higher percentage of 
CD19
+
IgD
−
GL7
+
FAS
+
 GC B cells in splenocytes from the CD8α− DC targeted group (Figures 3-9A and 
B). The titers of IgM were comparable between CD8α+ and CD8α− DCs targeted groups at day 3. At day 
5, higher IgM and IgG titers from the CD8α− DC targeted group were observed when compared with 
those induced by CD8α+ DCs (Figure 3-9C). 
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3.4. Discussion 
 
Modulating the induction of Tfh cell differentiation is the major step to potentially treat dysfunctional 
humoral immune responses. However, the induction of Tfh cells by DCs has not been clearly understood. 
In the present study, we examined the unknown intrinsic features of the two myeloid DC subsets 
important for the initiation of Tfh cell induction. 
The localization of DCIR2
+
CD4
+
 DCs (equivalent to CD8α− DCs in this study) in the MZ bridging 
channel/inter-follicular region has been reported to be mediated via the chemotactic receptor EBI2 (Yi 
and Cyster, 2013, Gatto et al., 2013), which has an important function in inducing blood-borne 
particulate antigen specific CD4
+
 T cell and B cell immune responses. Supported by these previous 
reports, we demonstrate that the localization of DCIR2
+
 CD8α− DCs may provide advantages in the 
initiation of Tfh cell differentiation given the fact of the early recruitment of antigen specific CD4
+
 T 
cells primed by CD8α− DCs into MZ bridging channels 1 day after the immunization. Moreover, the 
migration of these CD4
+
 T cells into the MZ bridging channels was presumably mediated via the high 
level of CXCR5 and the low level of CCR7 expressions, consistent with the previous reports (Hardtke et 
al., 2005, Haynes et al., 2007). CD8α+ DC primed CD4+ T cells expressed low level of CXCR5 and high 
level of CCR7, which may make them be retained in the localization of the T cell enriched region, 
resulting in the differentiation to IFN-γ secreting Th1 cells (Shin et al., 2015). 
Secretory cytokines often determine the fate of various effector CD4
+
 T cell subsets (Ottenhoff, 2012), 
and IL-6 has been reported as a major cytokine in inducing Tfh cell differentiation (Ballesteros-Tato and 
Randall, 2014). We demonstrated that CD8α− DCs properly induced Tfh cells as well as Tfh cell 
dependent humoral immune responses both in the presence of poly (I:C) and LPS (Figure 3-10A and B) 
(Shin et al., 2015). However, the two myeloid DC subsets showed opposites in the level of IL-6 secretion 
in the presence of poly (I:C) and LPS stimulation, indicating the insignificance of IL-6 secreted from the 
DC subsets in inducing Tfh cells. Instead, the high levels of autocrine IL-6 (Figure 3-6C) secreted from 
the antigen specifically activated CD4
+
 T cells induced by CD8α− DCs, regardless of the adjuvant types, 
seem to be important in inducing Tfh cell differentiation. The pro-inflammatory cytokines IL-1β and 
TNF-α highly secreted from CD8α+ DCs in the presence of both poly (I:C) and LPS, may be involved in 
inducing other effector CD4
+
 T cell subsets (Ottenhoff, 2012). 
The advantageous localization of CD8α− DCs in MZ bridging channels to encounter antigen specific B 
cells (Chappell et al., 2012) and their slow rate of antigen internalization for prolonged antigen 
presentation (Dudziak et al., 2007) have been reported, which may help B cells to uptake antigens easily, 
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resulting in highly activated antigen specific B cells. However, the dominance of CD8α− DCs over other 
APCs including B cells in the initiation of functional Tfh cells with excess OVA antigens has been 
confirmed. Nonetheless, given the previous reports demonstrating that the deficiency of functional B 
cells resulted in the decreased number of Tfh cells (Haynes et al., 2007, Johnston et al., 2009) and other 
DC subsets such as late activator antigen-presenting cells (Yoo et al., 2012) or monocyte-derived DCs 
(Chakarov and Fazilleau, 2014) induced Tfh cell differentiation through different types of immune 
responses, further studies are required to understand how other APCs interplay each other in the 
induction of Tfh cell differentiation. 
Together with highly enhanced ICOSL and OX40L expressed on CD8α− DCs in inducing Tfh cells (Shin 
et al., 2015), supported by the previous reports demonstrating the significant role of ICOSL and OX40L 
on dendritic cells or APCs in Tfh cell differentiation (Choi et al., 2011, Jacquemin et al., 2015), the 
localization of the CD8α− DC subset in MZ bridging channels may deliver synergic effects in Tfh cell 
induction. The difference in antigen processing (Dudziak et al., 2007) and the duration of antigen 
presentation (Deenick et al., 2010, Lahoud et al., 2011) are other factors in DC subsets that may need to 
be considered for Tfh cell differentiation. 
In conclusion, we demonstrate the unknown intrinsic features of CD8α− DCs, proposing its specialty in 
inducing functional Tfh cells. Based on the results we showed so far, we present a rationale to find the 
counterpart of CD8α− DCs in humans to develop efficient DC-based vaccines for improved T cell 
dependent humoral immune responses. 
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Figure 3-1. CD4
+
 T cells primed by CD8α− DCs localized in the MZ bridging channels. OVA specific 
DO11.10
+
CD4
+
 T cells were adoptively transferred to naive BALB/c mice at day -1, and were immunized 
subcutaneously (s.c.) either with αDEC:OVA (CD8α+ DC targeting) or αDCIR2:OVA (CD8α− DC 
targeting) conjugated monoclonal antibodies (mAbs) in the presence of poly (I:C) at day 0. At each 
indicated time point after the immunization, immunohistochemical staining of spleen sections from each 
group was prepared and detected by fluorescence confocal microscopy. IgD, green; DO11.10, red; 
DEC205 (for DEC205 targeted group) or 33D1 (for 33D1 targeted group), blue. Data are representative of 
three or more independent experiments (n > 10 per group). 
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Figure 3-2. Induction of ICOS
+
PD1
+
 Tfh cells by CD8α− DCs in vivo. (A−D) OVA specific 
DO11.10
+
Thy1.1
+
CD4
+
 T cells were adoptively transferred to naive Thy1.2
+ 
BALB/c mice at day -1, and 
were immunized s.c. with PBS, soluble OVA protein (OVA protein), or either αDEC:OVA (CD8α+ DC 
targeting) or αDCIR2:OVA (CD8α− DC targeting) conjugated mAbs in the presence of poly (I:C) at day 0. 
At each indicated time points after the immunization, lymph node (LN) or spleen (SP) cells were prepared 
and Tfh cells gated from the Thy1.1
+
CD4
+
 T cells were analyzed. (A and C) Representative flow 
cytometry plots of CD44
+
ICOS
+ 
(A) or CD44
+
PD1
+
 (C) Tfh cells. (B and D) Data represent mean ± s.e.m. 
of three independent experiments described in (A) or (C), respectively. * P < 0.05, ** P < 0.01, *** P < 
0.001. (A−D, n=3 per group). 
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Figure 3-3. Induction of CXCR5
+
Bcl6
+
 or CXCR5
+
IL-21
+
 Tfh cells by CD8α− DCs in vivo. (A and B) 
OVA specific DO11.10
+
Thy1.1
+
CD4
+
 T cells were adoptively transferred to naive Thy1.2
+ 
BALB/c mice 
at day -1, and were immunized s.c. with PBS, soluble OVA protein (OVA protein), or either αDEC:OVA 
(CD8α+ DC targeting) or αDCIR2:OVA (CD8α− DC targeting) conjugated mAbs in the presence of poly 
(I:C) at day 0. 5 days after the immunization, lymph node cells were prepared and Tfh cells gated from 
the Thy1.1
+
CD4
+
 T cells were analyzed. (A) Representative flow cytometry plots of CXCR5
+
Bcl6
+ 
or 
CXCR5
+
IL-21
+ 
Tfh cells. (B) Data represent mean ± s.e.m. of two independent experiments described in 
(A). ** P < 0.01. (n=3 per group). 
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Figure 3-4. Induction of CXCR5
+
CCR7
low
 Tfh cells by CD8α− DCs in vivo. (A−D) OVA specific 
DO11.10
+
Thy1.1
+
CD4
+
 T cells were adoptively transferred to naive Thy1.2
+ 
BALB/c mice at day -1, and 
were immunized s.c. with PBS, soluble OVA protein (OVA protein), or either αDEC:OVA (CD8α+ DC 
targeting) or αDCIR2:OVA (CD8α− DC targeting) conjugated mAbs in the presence of poly (I:C) at day 0. 
At each indicated time points after the immunization, lymph node (LN) or spleen (SP) cells were prepared 
and Tfh cells gated from the Thy1.1
+
CD4
+
 T cells were analyzed. (A and C) Representative flow 
cytometry plots of CD44
+
CXCR5
+ 
(A) or CD44
+
CCR7
low
 (C) Tfh cells. (B and D) Data represent mean ± 
s.e.m. of three independent experiments described in (A) or (C), respectively. * P < 0.05, ** P < 0.01, *** 
P < 0.001. (A−D, n=3 per group). 
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Figure 3-5. The proliferation of CD4
+
 T cells induced by the two DC subsets in vivo. OVA specific 
DO11.10
+
Thy1.1
+
CD4
+
 T cells were adoptively transferred to naive Thy1.2
+
Balb/c mice at day -1, s.c. 
immunized with PBS (PBS), OVA protein (OVA protein), αDEC:OVA (CD8α+ DC targeting), or 
αDCIR2:OVA (CD8α− DC targeting) conjugated antibodies in the presence of LPS at day 0. At each 
indicated time point after the immunization, lymph node (LN) or spleen (SP) cells were prepared and Tfh 
cells gated from the DO11.10
+
CD4
+
CD44
+ 
T cells were analyzed. Proliferation of OVA specific 
DO11.10
+
Thy1.1
+
CD4
+
 T cells was analyzed by CFSE dilution assay. Data are representative of two 
independent experiments. (n=3-4 per group). 
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Figure 3-6. IL-6 cytokine from the DC subsets or the DC subset induced CD4
+
 T cells. (A and B) 
ELISA analysis of the cytokines, IL-1β, IL-6, TNF, secreted from the two DC subsets stimulated either 
with poly (I:C) (A) or LPS (B) for 12 or 24 hours. * P < 0.05. Data represent mean ± s.e.m. of three 
independent experiments (A and B). (C) OT-II OVA specific Vα2+CD4+ T cells were co-cultured with 
each DC subset in the presence of OVA peptide (323-339) either with poly (I:C) or LPS. After 3 days of 
the co-culture, the level of IL-6 cytokine in the supernatant was measured by ELISA. ** P < 0.01. 
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Figure 3-7. Maturation markers on the DC subsets. Maturation markers on the two DC subsets. The 
two DC subsets were stimulated either with poly (I:C) or LPS for 0 (immature) or 24 hours (mature). 
Representative histograms of CD80, CD86 or MHCII on the DC subsets. Data are representative of three 
independent experiments.  
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Figure 3-8. CD8α− DCs specialize in inducing Tfh cells in vivo. OVA specific DO11.10+CD4+ T cells 
were adoptively transferred to naive Balb/c mice at day -1, and were immunized s.c. either with 
αDEC:OVA (CD8α+ DC targeting) or αDCIR2:OVA (CD8α− DC targeting) conjugated mAbs in the 
presence of soluble OVA protein + LPS. 5 days after the immunization, lymph node cells (A and B) or 
spleen cells (C and D) were prepared and Tfh cells gated from the DO11.10
+
CD4
+
CD44
+ 
T cells were 
analyzed. (A and C) Representative FACS plots of CXCR5
+
PD1
+
, CXCR5
+
Bcl6
+
, or CXCR5
+
IL-21
+
 Tfh 
cells. (B and D) Data represent mean ± s.e.m. of three independent experiments described in (A and C), 
respectively. * P < 0.05, ** P < 0.01.  (n=3 per group). 
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Figure 3-9. CD8α− DCs are superior in generating efficient humoral immune responses in vivo. OVA 
specific DO11.10
+
CD4
+
 T cells were adoptively transferred to naive 
 
Balb/c mice at day -1, and were 
immunized s.c. either with αDEC:OVA (CD8α+ DC targeting) or αDCIR2:OVA (CD8α− DC targeting) 
conjugated mAbs in the presence of soluble OVA protein + LPS. At each indicated time point after the 
immunization, data were analyzed. (A) Representative FACS plots of GL7
+
FAS
+ 
GC B cells gated from 
CD19
+
IgD
− 
splenocytes. (B) Data represent mean ± s.e.m. of three independent experiments described in 
(A). (C) ELISA analyses of OVA-specific serum IgM or IgG antibodies. Data represent mean ±  s.e.m. 
of three independent experiments. *** P < 0.001.  (n=3 per group). 
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Figure 3-10. Efficient humoral immune responses are induced by CD8α− DCs in vivo. (A and B) 
OVA specific DO11.10
+
Thy1.1
+
CD4
+
 T cells were adoptively transferred to naive Thy1.2
+ 
Balb/c mice at 
day -1, ans were immunized s.c. either with PBS, OVA protein (OVA protein), αDEC:OVA (CD8α+ DC 
targeting), or αDCIR2:OVA (CD8α− DC targeting) conjugated mAbs in the presence of LPS. At the 
indicated time point, ELISA analyses of OVA−specific serum IgM antibodies were performed. Data 
represent mean±s.e.m. of four independent experiments. * P < 0.05, *** P < 0.001, n.s. (not significant). 
(n=4 per group). 
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Conclusion 
 
Rapidly accumulating data on T follicular helper (Tfh) cells for the last 10 years has enlightened our 
understanding on T cell-dependent humoral immunity. However, how dendritic cells (DCs) polarize 
antigen-specific Tfh cells differently from various other CD4
+
 effector T cell subsets still remain unclear. 
Here we investigated the unknown intrinsic features of the two distinct myeloid DC subsets, CD8α+ DCs 
and CD8α− DCs, and demonstrated an unexplored role of cellular and molecular mechanisms of CD8α− 
DCs to promote antigen-specific functional Tfh cell differentiation. In addition, we showed that efficient 
humoral immune responses were induced by utilizing CD8α− DCs against various human pathogenic 
antigens such as Y. pestis LcrV, human immunodeficiency virus (HIV) Gag, and hepatitis B surface 
antigen (HBsAg). This study proposes a new paradigm on Tfh cell research field by elucidating how DCs 
influence Tfh cell fate providing rationale to enhance humoral immunity. This study suggests that even a 
small amount of antigen delivered directly to CD8α− DCs is sufficient to induce fully functional Tfh cells, 
providing a rationale for targeting the CD8α− DC subset for efficient DC-based therapies, which will be of 
great interest to broad readership - including basic scientists and clinicians - interested in regulating 
humoral immunity for improved vaccine and novel therapy development.  
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